Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy: Cause and effect?

Kelly A Aromolaran¹ and Peter A Goldstein¹,²

Abstract
Cancer is the second leading cause of death worldwide and is a major global health burden. Significant improvements in survival have been achieved, due in part to advances in adjuvant antineoplastic chemotherapy. The most commonly used antineoplastics belong to the taxane, platinum, and vinca alkaloid families. While beneficial, these agents are frequently accompanied by severe side effects, including chemotherapy-induced peripheral neuropathy (CPIN). While CPIN affects both motor and sensory systems, the majority of symptoms are sensory, with pain, tingling, and numbness being the predominant complaints. CPIN not only decreases the quality of life of cancer survivors but also can lead to discontinuation of treatment, thereby adversely affecting survival. Consequently, minimizing the incidence or severity of CPIN is highly desirable, but strategies to prevent and/or treat CPIN have proven elusive. One difficulty in achieving this goal arises from the fact that the molecular and cellular mechanisms that produce CPIN are not fully known; however, one common mechanism appears to be changes in ion channel expression in primary afferent sensory neurons. The processes that underlie chemotherapy-induced changes in ion channel expression and function are poorly understood. Not all antineoplastic agents directly affect ion channel function, suggesting additional pathways may contribute to the development of CPIN. Indeed, there are indications that these drugs may mediate their effects through cellular signaling pathways including second messengers and inflammatory cytokines. Here, we focus on ion channelopathies as causal mechanisms for CPIN and review the data from both pre-clinical animal models and from human studies with the aim of facilitating the development of appropriate strategies to prevent and/or treat CPIN.

Keywords
Cancer, chemotherapy-induced peripheral neuropathy, neuropathic pain, ion channel, antineoplastic, taxane, platinum, vinca alkaloid

Date received: 9 March 2017; revised: 12 May 2017; accepted: 16 May 2017

Introduction
Cancer (all sites) presents an enormous global disease burden. In 2015, 17.5 million new cases were diagnosed, and there were 8.7 million cancer deaths. The lifetime risk of developing cancer is one in three for men and one in four for women. In men, prostate cancer was the most common, while cancers of the trachea, bronchi, and lung were the leading causes of cancer death. In women, breast cancer was the most common cancer as well as the leading cause of cancer deaths.¹ Treatment options are tumor and patient specific, and routinely include, alone or in combination, surgery, radiation therapy, immunomodulatory therapy, and adjuvant antineoplastic chemotherapy. Among the antineoplastics commonly encountered in the aforementioned settings are those belonging to the taxane, platinum, and vinca alkaloid families.²–⁶ Although efficacious, these agents are associated with significant, debilitating, adverse side effects, including chemotherapy-induced peripheral neuropathy (CIPN). As cancer survival rates have

¹Department of Anesthesiology, Weill Cornell Medical College, New York, NY, USA
²Department of Medicine, Weill Cornell Medical College, New York, NY, USA

Corresponding author:
Kelly A Aromolaran, Department of Anesthesiology, Weill Cornell Medical College, 1300 York Avenue, Room A-1040, New York, NY 10065, USA.
Email: kaa2046@med.cornell.edu
Molecular Pain

improved, the burden of CIPN has correspondingly increased. CIPN can affect both sensory and motor systems and has a profound negative impact on long-term quality of life (QoL). There is evidence that patients deem CIPN to be so unacceptable that they are willing to discontinue treatment despite the potential for a decrease in survival.10

The symptoms of CIPN are mainly sensory, with pain (including hypersensitivity to cool temperatures), tingling, and numbness (especially in the hands and feet), being the predominant complaints.9–11 The distal distribution of the sensory complaints reflects the fact that large sensory nerve fibers are most commonly affected. In fact, dorsal root ganglion (DRG) neurons are a prominent target, possibly due to the fact that they are less protected by the blood–brain barrier.8,11 Motor symptoms are also encountered and include weakness, cramps, and gait dysfunction; sweating abnormalities, constipation, and light-headedness are evidence of autonomic symptoms.8,9

The symptoms of CIPN can be clinically assessed and graded. While there are several grading scales (including specific chemotherapy symptom scales), the two commonly employed scales are: (1) The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE or just NCI) and (2) The Total Neuropathy Score. Both scales are graded from 0 to 4 for each effect measured, with 4 indicating the greatest degree of severity. The NCI scale has a limited scoring range (0–4) because it only takes into account sensory effects and requires significant training to obtain high user reliability; in contrast, the Total Neuropathy Score scale has a wider scoring range (0–32 in total) as it includes sensory symptoms, motor symptoms, pin sensitivity, vibration sensitivity, strength, deep tendon reflexes, and neurophysiological effects from the sural and peroneal nerve and is considered reliable, having a high inter-observer reliability. 11,12

The lack of a standardized approach to assess or grade CIPN can lead to variability in determining the prevalence of CIPN.11,13 Depending on the drug regimen, the overall rate of CIPN ranges from 19% to 85%.13,14 The incidence rate, however, is time sensitive; Seretny et al. compiled data from 31 different studies and found that within the first month following chemotherapy treatment, ~68% of patients had CIPN, by three months, 60% still had CIPN, and after six months, 30% were still affected. Another reason for the variability in the rate of occurrence may be due to differences in the chemotherapeutics themselves. As noted above, the three main chemotherapeutic classes commonly associated with CIPN are as follows: taxanes, platinum-based agents, and vinca alkaloids. The taxanes, which include paclitaxel, docetaxel, and cabazitaxel, are used to treat breast, ovary, non-small cell lung, gastric, head and neck, and prostate cancers. In contrast, platinum drugs, including cisplatin, carboplatin, and oxaliplatin, are used to treat cancers localized to the testes, ovary, cervix, uterus, head and neck, colon, and prostate. Finally, the vinca alkaloids, which include vincristine, vinblastine, vindesine, and vinorelbine, target hematologic cancers and pediatric sarcomas. Each antineoplastic class has a different mechanism of action and dose/rate of CIPN occurrence; it is therefore crucial to assess each one individually in order to reveal unique and/or common mechanisms involved in the pathogenesis of CIPN. One common mechanism to all three antineoplastic classes is changes in ion channel expression in primary afferent sensory neurons. In this review, we focus on this common pathway and review data from pre-clinical animal models as well as data from human studies where such exists. By better understanding common pathways, it may be possible to develop appropriate strategies to treat CIPN, or even better, prevent its onset.

Taxanes

Taxanes exert their effect by preventing the depolymerization of microtubules, leading to both apoptosis and the inhibition of axonal protein transport, thereby altering the function of distal sensory axons, either or both of which can result in CIPN.8,9,15 The incidence of CIPN can vary depending on the dose per cycle, duration of infusion, cumulative dose, and treatment schedule, with paclitaxel more likely than docetaxel to cause CIPN.10,11,16

Paclitaxel

The incidence of paclitaxel-induced CIPN varies as a consequence of a number of factors: (1) the cumulative dose, the total dose at which CIPN symptoms first appear is >300 mg/m2, while a dose between 1400 and 1500 mg/m2 has been linked to Grade 3 neuropathy; (2) rapid rate of infusion, there is increased neuropathy with a 3 h versus 24 h infusion duration; and (3) increased single dose, symptoms can start 24 to 72 h after administration of a single (high) dose of 250 mg/m2 but usually occurs after multiple doses of the conventional dose of <200 mg/m2.10,11,16,17

Paclitaxel can cause an acute pain syndrome that develops one to four days after initiating chemotherapy and is characterized by myalgia and arthralgia.11 This acute pain syndrome is predictive of future development and severity of paclitaxel-induced CIPN.11,17 While mild symptoms can improve with reduction in dose, paclitaxel-induced neuropathy can persist for months to years.10 In the short term (i.e., 12 months), ~80% of breast cancer patients treated with paclitaxel
developed numbness in the hands and feet\(^{18}\), the duration and incidence of CIPN may also be influenced by the specific cancer under treatment as Pignata et al.\(^{19}\) reported that in patients with ovarian cancer, the probability of having CIPN after six months was 15% and 11% after two years. Alternatively, the differences in the incidence rates could also reflect drug-drug interactions as patients in the Pignata study received both carboplatin and paclitaxel. On average, while 50% of patients with paclitaxel-induced CIPN show recovery after nine months, roughly 40% of patients still display symptoms after three years.\(^{8,10,11}\)

**Docetaxel**

Docetaxel-associated CIPN occurs at cumulative doses of >100 mg/m\(^2\), is milder than that associated with paclitaxel, and can resolve spontaneously following cessation of therapy.\(^{10,16}\) In contrast to paclitaxel, Grade 3/4 neurotoxicity occurs in <10% of patients, but is proportional to cumulative dose.\(^{10,16}\) While it may not be as severe as paclitaxel, up to one-third of patients treated with docetaxel will have CIPN that persists anywhere from 3 to 13 years after completing treatment.\(^{20,21}\) Therefore, even “mild” to “moderate” CIPN can still affect a large number of patients for extended periods of time and further underscores the need for effective treatments and/or protective strategies.

**Platinum compounds**

Platinum compounds, including carboplatin, cisplatin, and oxaliplatin, form platinum adducts that promote cross linking that can alter nuclear DNA structure and synthesis,\(^{22,23}\) as well as mitochondrial DNA, leading to oxidative stress.\(^ {9,17}\) As a class, they contribute to the development of CIPN by impairing the electrophysiologic function of DRG neurons as demonstrated by a reduction and/or loss of the sensory action potential in nerve conduction studies.\(^9\) Compared to cisplatin and oxaliplatin, carboplatin-induced CIPN is less severe and less common, occurring in 4% to 6% of patients.\(^{10,24}\)

**Cisplatin**

The risk of developing cisplatin-induced CIPN increases with cumulative dose and higher single dose administration.\(^ {8,11,25}\) The cumulative dose associated with risk of neurotoxicity is >350 mg/m\(^2\).\(^ {26}\) A common experience with cisplatin is the phenomenon known as “coasting,” wherein CIPN symptoms can worsen or start after completion of therapy.\(^ {10}\) Recovery is quite prolonged and is often incomplete, largely due to the fact that the platinum adducts can persist in body tissues for years.\(^ {27}\) When patient serum was tested 20 years after treatment, platinum levels were still elevated and the levels were associated with the severity of neuropathy.\(^ {28}\) Thus, it is not surprising that studies have found patients suffering from CIPN long after their treatment has ended. One such study found 20% of patients treated with cisplatin had persistent sensory neuropathy,\(^ {26}\) while another reported that overall, 80% of patients had demonstrable nerve damage, with 28% of patients remaining symptomatic 15 years after treatment, with 6% having severe, disabling CIPN.\(^ {9,11,29}\)

**Oxaliplatin**

The incidence of CIPN after oxaliplatin treatment also increases with cumulative dose, single dose, and rapid infusion rate.\(^ {11,30,31}\) Severe neuropathy occurs in 10% of patients after nine cycles of chemotherapy and up to 50% of patients after 14 cycles.\(^ {32}\) The cumulative dose associated with peripheral neuropathy is >550 mg/m\(^2\),\(^ {9,11,15}\) and with a cumulative dose of 750 to 850 mg/m\(^2\), 82% to 93% of patients experience some form of CIPN, with 12% to 34% of patients experiencing severe (Grade 3/4) neuropathy.\(^ {10,11,32,33}\)

Oxaliplatin-induced neuropathy is characterized by two distinct syndromes. First, there is the acute syndrome (which appears to be unique to oxaliplatin among the platinum compounds), which occurs during or immediately after administration of oxaliplatin, is seen in the majority of patients (85%–95%), can be triggered by cold, is characterized by neuronal hyperexcitability, and can resolve in hours or days after onset.\(^ {34-37}\) Second, there is a chronic syndrome, which is comparable to the neuropathy seen with cisplatin and other platinum compounds where “coasting” occurs.\(^ {9,35}\) This chronic syndrome can affect 80% to 90% of patients, with 40% to 50% of patients experiencing at least Grade 2 symptoms, while 10% to 20% had Grade 3 or 4 symptoms.\(^ {10,35,38}\) Although oxaliplatin-induced CIPN is largely reversible with an average time of recovery of 13 weeks, some patients experience persistent neuropathy.\(^ {11}\) It is important to note that what patients report (i.e., what is their subjective experience of their disease) is not necessarily the same as that which is “objectively” measured clinically. Objective assessment, such as with doctor scored NCI assessment or via nerve conduction studies, indicates that lasting abnormalities and decreased sensory amplitudes can be detected in 10% to 75% of patients up to six years after treatment is terminated.\(^ {9,31,39,40}\) But this is not necessarily a foolproof diagnostic tool. Thus, one study reported that on clinical assessment with the NCI scale, 10% of patients will have objective measures consistent with a diagnosis of CIPN two years after treatment has ended even
though 60% of patients will report symptoms consistent with lasting neuropathy when asked to describe how they are feeling\textsuperscript{31}; elsewhere, patients have reported significant symptoms up to 11 years after treatment ended,\textsuperscript{42} again indicating that clinical assessment does not fully account for what the patient is experiencing. Conversely, there are instances where the incidence of patient reports of neuropathic symptoms is less than that as evidenced by altered nerve conduction studies; in that same study by Bennett et al.,\textsuperscript{41} while 60% of patients reported lasting neuropathy symptoms, 85% of patients demonstrated signs of neuropathy as measured via nerve conduction studies, suggesting that some patients with chronic symptoms may learn to “adapt” to their sensory abnormalities.\textsuperscript{11} Such discordance demonstrates the need for improving our clinical assessment tools and/or the need to more adequately account for a patient’s subjective experience when diagnosing CIPN.

Vinca alkaloids

Vincristine, one of the vinca alkaloids, is among the more toxic chemotherapy agents, and nearly all patients treated with vincristine develop some degree of neuropathy.\textsuperscript{9,10} Vincristine produces a loss of microtubules by preventing tubulin polymerization, which results in impaired axonal transport.\textsuperscript{9,10} Patients with vincristine-induced neuropathy have reduced amplitudes of both motor and sensory action potentials as well as slightly reduced conduction velocities.\textsuperscript{9} The toxicity due to vincristine is both cumulative and dose dependent, with a dose-related threshold of >4 mg/m\textsuperscript{2} and severe neuropathy occurring after a cumulative dose of 15 to 20 mg/m\textsuperscript{2}.\textsuperscript{9–11,43,44}

Similar to cisplatin, “coasting” is common to patients treated with vincristine; it is seen in approximately 30% of patients, and the most common symptoms experienced are numbness and tingling in the hands and feet, which are seen in 35% to 45% of patients.\textsuperscript{9–11,43,44} At least one study has suggested that vincristine-induced CIPN is largely reversible with good long-term prognosis,\textsuperscript{10} whereas others studies have found that vincristine-induced CIPN persists for extended periods of time.\textsuperscript{11} Mild sensory symptoms were seen in 32% of non-Hodgkin lymphoma survivors 34 months after the end of treatment, while 14% still had symptoms after nine years.\textsuperscript{11,45} In addition, 30% of children with acute lymphoblastic leukemia still had CIPN symptoms seven years after the end of treatment.\textsuperscript{46} These studies are a reminder that while the prognosis (in terms of survival) may be good for the majority of vincristine-induced neuropathy patients, there are still many that suffer with a diminished long-term QoL and who need effective treatment for their neuropathy.

Despite the fact that distinct chemotherapeutic agents have different modes of action, many produce a long-lasting peripheral neuropathy, which has significant public health ramifications. No uniformly effective treatments for CIPN exist, indicating that there is a pressing need to develop effective therapeutic strategies. There is increasing evidence that pain, both physiologic and pathologic, is associated with ion channel regulation and/or modulation to regulate neuronal activity in the peripheral nervous system.\textsuperscript{47} Therefore, a clear understanding of how the functional expression of major neuronal ionic channels is altered by chemotherapy-related drugs will ideally reveal novel therapeutic targets that will help prevent or treat CIPN (Tables 1 and 2). It is also possible that chemotherapy drugs do not act directly on ion channels, and second messengers such as cytokines could provide a link between the two as they are already implicated in pain\textsuperscript{82,83} and ion channel regulation.\textsuperscript{84,85} Therefore, the aim of this article is to review current research in the context of neuronal ion channels and pathways that are modulated by chemotherapeutic agents with the hope that it will reveal new and unappreciated research areas that warrant further investigation.

Neuronal excitation

Action potentials (APs) can encode information in their firing frequency and pattern, and perpetuate signal transmission as they propagate down the nerve axon and invade the axon terminal, where the resulting membrane depolarization initiates the sequence of steps necessary for vesicle mobilization, fusion, and exocytosis. APs are generated by the activation of ion channels. There are three main phases of the AP: (1) the depolarization phase—which consists of the upstroke and overshoot where the membrane potential becomes positive, (2) the repolarization phase—which consists of the downstroke after the depolarization phase and returns the cell’s membrane potential to a negative potential (resting membrane potential), and (3) the after-hyperpolarization phase (AHP)—which is when the membrane potential falls below the resting membrane potential before returning to the resting state. Different ion channels are responsible for generating and sustaining the different phases.\textsuperscript{86} Voltage-gated Na\textsuperscript{+} channels mediate the depolarization phase, voltage-gated Ca\textsuperscript{2+} and K\textsuperscript{+} channels mediate the repolarization phase, K\textsuperscript{+} channels are responsible for the AHP, and K\textsuperscript{+}, Na\textsuperscript{+}, and HCN channels are responsible for setting the resting membrane potential, all of which help control the excitability of neurons.\textsuperscript{86} We will briefly discuss each of these ion channel families, as well as Transient Receptor Potential (TRP) channels, and their role in CIPN.
Sodium channels

Biophysics

Voltage-gated Na$^+$ (Na$_V$) channels are one of the more prominent ion channels associated with CIPN. The first indications of their involvement come from studies where administration of oxaliplatin increased the time course and amplitude of compound action potentials in A-fibers of rat sural and vagal nerves, indicating that Na$_V$ (with possible effects on K$_V$ channels as well) were modulated by this agent. The Na$_V$ family consists of nine members; six members are sensitive to the organic blocker tetrodotoxin (TTX) (Na$_V$1.1–1.4, 1.6, and 1.7), and three are insensitive (Na$_V$1.5, 1.8, and 1.9). Subsequent research turned to studying this modulation in heterologous expression systems in order to obtain greater mechanistic insights into chemotherapeutic modulation of Na$_V$ channel function.

At the biophysical level, oxaliplatin can decrease the peak amplitude of Na$^+$ currents in NG108-15 neuronal cells (and in HEK293 cells in which Na$_V$1.5 channels were heterologously expressed). Oxalate, but not dichlorodiaminocyclohexane platinum (which are the two main metabolites of oxaliplatin) decreases total Na$^+$ currents in a Ca$^{2+}$-dependent manner, suggesting that Na$^+$ current inhibition by oxaliplatin results from Ca$^{2+}$ immobilization by oxalate.

In contrast, other groups have shown that oxaliplatin can shift the voltage of activation to more negative potentials as well as slow inactivation at negative membrane potentials, thereby leading to an increase in total Na$^+$ current and an increase in membrane excitability. This oxaliplatin-induced stabilization of the open state occurs with Na$_V$1.6 channels.

Animal studies

In vivo models of CIPN have added to our understanding of the important role that Na$_V$ channels play in the pathogenesis of CIPN. In general, TTX blocks the development of paclitaxel-induced mechanical and cold allodynia and blocks oxaliplatin-induced nerve hyperexcitability in mice; those data emphasize that TTX-sensitive Na$_V$...
channels play a key role in the development of CIPN. Underscoring the role of Na\textsubscript{v}1.6 in particular is the observation that oxaliplatin-induced increases in TTX-sensitive Na\textsuperscript{+} currents were absent in DRGs from Na\textsubscript{v}1.6\textsuperscript{-/-} mice.\textsuperscript{56} The centrality of Na\textsubscript{v}1.6 in this process is highlighted by additional gene deletion studies demonstrating that oxaliplatin- or vincristine-induced mechanical or cold allodynia is preserved in Na\textsubscript{v}1.3, 1.7, 1.8, or 1.9 null mice.\textsuperscript{77,81} To exclude a role for these channels in CIPN may, however, be premature. Disease states that alter the expression and function of ion channels are not the same and may not produce the same physiological effect as

| Antineoplastic agent | In vivo ion channel modulation in CIPN |
|---------------------|---------------------------------------|
| **Taxanes**         |                                       |
| Paclitaxel          | Na\textsuperscript{+} channels        |
|                     | TTX blocks mechanical and cold allodynia\textsuperscript{69} |
|                     | Ca\textsuperscript{2+} channels       |
|                     | N-type inhibitor reduced acute mechanical hyperalgesia and chronic pain\textsuperscript{70} |
|                     | T-type inhibitor or Ca\textsubscript{v}3.2\textsuperscript{-/-} reversed mechanical and/or cold allodynia/hyperalgesia\textsuperscript{54,71,72} |
|                     | \(\alpha_2\delta\) inhibitor reduced mechanical allodynia and hyperalgesia\textsuperscript{49–52,73} |
|                     | TRP channels                          |
|                     | TRPA1\textsuperscript{1/-} or inhibitor inhibits mechanical and cold allodynia and heat hyperalgesia\textsuperscript{74,75} |
|                     | TRPV4 inhibitor inhibits mechanical allodynia and heat hyperalgesia\textsuperscript{74,75} |
|                     | TRPV1 antagonists prevent thermal hyperalgesia and mechanical hypersensitivity\textsuperscript{53,75} |
| **Platinum compounds** |                                       |
| Cisplatin           | Ca\textsuperscript{2+} channels       |
|                     | N-type inhibitor prevented development of neuropathic pain\textsuperscript{55} |
|                     | TRP channels                          |
|                     | TRPA1 antagonist reversed mechanical allodynia\textsuperscript{76} |
| Oxaliplatin         | Na\textsuperscript{+} channels        |
|                     | Na\textsubscript{v}1.4 and Na\textsubscript{v}1.8 human polymorphisms increase incidence/severity\textsuperscript{61} |
|                     | Na\textsubscript{v}1.7 inhibitor produced anti-hyperalgesia\textsuperscript{63} |
|                     | Na\textsubscript{v}1.3\textsuperscript{1/-}, Na\textsubscript{v}1.7\textsuperscript{1/-}, Na\textsubscript{v}1.8\textsuperscript{1/-}, or Na\textsubscript{v}1.9\textsuperscript{1/-} mice still experienced mechanical and cold allodynia\textsuperscript{77} |
|                     | Na\textsubscript{v}1.9\textsuperscript{1/-} alleviates cold hyperalgesia and allodynia\textsuperscript{65} |
|                     | K\textsuperscript{+} channels         |
|                     | HCN1 inhibitor prevented cold hypersensitivity and mechanical hyperalgesia\textsuperscript{62,78} |
|                     | TREK1\textsuperscript{1/-} and TRAAK\textsuperscript{1/-} mice did not experience cold hypersensitivity\textsuperscript{64} |
|                     | TREK2\textsuperscript{1/-} mice did not experience cool hypersensitivity\textsuperscript{64} |
|                     | K\textsubscript{C\textsubscript{c}}\textsubscript{2.3} length of CAG repeats related to neuropathy\textsuperscript{79} |
|                     | KCNQ1 inhibitor induced/activator decreased orofacial cold hyperalgesia\textsuperscript{67} |
|                     | Ca\textsuperscript{2+} channels       |
|                     | \(\alpha_2\delta\) inhibitor reduced mechanical allodynia and hyperalgesia\textsuperscript{50} |
|                     | TRP channels                          |
|                     | TRPM8 inhibitors prevented cold allodynia\textsuperscript{50} |
|                     | TRPA1\textsuperscript{1/-} mice or inhibitors blocked/reversed cold and mechanical hyperalgesia\textsuperscript{76,80} |
| **Vinca alkaloids** |                                       |
| Vincristine         | Na\textsuperscript{+} channels        |
|                     | Na\textsubscript{v}1.8 anti-sense still experienced mechanical allodynia\textsuperscript{81} |
|                     | Ca\textsuperscript{2+} channels       |
|                     | T-type inhibitor reversed mechanical allodynia/hyperalgesia\textsuperscript{72} |
|                     | \(\alpha_2\delta\) inhibitor reduced mechanical allodynia/hyperalgesia\textsuperscript{52,73} |

TRP: transient receptor potential.
deleting the channels before the actual disease or event occurs.\textsuperscript{47} In support of this idea, genetic analysis of nociceptor ion channel expression in mice exposed to oxaliplatin detected an increase in Na\textsubscript{V}1.8 mRNA,\textsuperscript{62} while Na\textsubscript{V}1.7 was increased following paclitaxel administration.\textsuperscript{48} More compellingly, a tocainide-derived Na\textsubscript{V}1.7-selective blocker, NeP1, produced anti-hyperalgesia after oxaliplatin administration.\textsuperscript{63} The real test for in vivo target engagement is, of course, to test the efficacy of NeP1 in Na\textsubscript{V}1.7 null mice following the induction of CIPN with oxaliplatin; those studies remain to be done.

A major complication with CIPN is cold hypersensitivity and cold-induced pain. In particular, the acute neuropathy caused by oxaliplatin is worsened by exposure to cold, and one study investigated the role oxaliplatin and its metabolites oxalate and dichlorodiaminocyclohexane platinum in both the acute (cold hyperalgesia/allodynia) versus chronic neuropathy (mechanical allodynia).\textsuperscript{92} Sakurai et al.\textsuperscript{92} found that oxalate, which can directly modulate Na\textsubscript{V} channels, contributes to the cold hyperalgesia/allodynia but dichlorodiaminocyclohexane platinum, which can bind DNA, contributes to mechanical allodynia but not cold-induced neuropathy suggesting a role for Na\textsubscript{V} channels in cold hyperalgesia/allodynia. In support of these findings, Na\textsubscript{V} channels have been shown to be modulated by cold and identified as cold sensors in nociceptive neurons.\textsuperscript{65,91–95} TTX-sensitive channels, but not those that are TTX-insensitive, are inhibited by cooling temperatures, thus TTX-insensitive channels are still active at cooler temperatures and are responsible for mediating cold sensation and pain.\textsuperscript{94} Two TTX-resistant Na\textsubscript{V} channels have been specifically attributed to sensing cold temperatures. Reducing temperatures shifts the voltage dependence of activation of Na\textsubscript{V}1.8 to more negative potentials, thereby facilitating its activation and increasing neuronal excitability.\textsuperscript{93} In addition, Na\textsubscript{V}1.8 null mice showed no response to noxious cold and mechanical stimuli at low temperatures.\textsuperscript{95} Like Na\textsubscript{V}1.8, Na\textsubscript{V}1.9 also shows increased activity in response to cool temperatures; thus, Na\textsubscript{V}1.9 null neurons showed impaired firing in response to cold temperatures, and Na\textsubscript{V}1.9 null mice and rats with Na\textsubscript{V}1.9 knocked down demonstrated increased cold pain thresholds. In fact, disrupting Na\textsubscript{V}1.9 alleviates oxaliplatin-induced cold hypersensitivity.\textsuperscript{65} Interestingly, Na\textsubscript{V}1.9 acts like an “amplifier” in cold sensing nociceptors by opening and producing a large sustained current near the resting potential, thereby amplifying sub-threshold depolarizations in the membrane potential produced by other co-localized ion channels, such as Na\textsubscript{V}1.8, and increasing overall excitability.\textsuperscript{65} In summary, the animal data strongly suggest that Na\textsubscript{V}1.6 to 1.9 all contribute to CIPN in vivo.

### Human studies

In addition to the in vitro and animal studies, there are human studies that further support the idea that Na\textsubscript{V} channels contribute to the development of CIPN.\textsuperscript{36,61,96} Two independent studies investigated excitability and nerve conduction in patients who had received treatment with oxaliplatin.\textsuperscript{36,96} Knowing that Na\textsubscript{V} channels play an important role activating and shaping the AP, as well as establishing and maintaining the resting membrane potential, Krishnan et al.\textsuperscript{96} used nerve conduction, specifically the compound AP measurements of the refractoriness and relative refractory period duration, to provide a connection between CIPN and Na\textsubscript{V} channel dysfunction. The relative refractory period is the time between APs when it is very difficult to generate another AP, and refractoriness is the percentage increase in current that is needed to generate an AP during the relative refractory period. Their results showed that oxaliplatin lead to increases in the refractoriness and relative refractory period, while patients were undergoing treatment and interestingly, they preceded the onset of clinical pain symptoms.\textsuperscript{96} These increases were the result of acute administration of oxaliplatin, and it is known that oxaliplatin produces an acute pain syndrome that is caused by the oxaliplatin metabolite, oxalate, directly affecting Na\textsubscript{V} channels.\textsuperscript{89} They also found that these early changes in the length of the median nerve AP refractory period were a predictor of the development of chronic neuropathy after oxaliplatin treatment, such that 78% of patients that had a refractory period of at least 4 ms (where normal duration is 3 ms), developed peripheral neuropathy,\textsuperscript{96} suggesting early changes in Na\textsubscript{V} channels could lead to long-term CIPN. In a similar study, Park et al.\textsuperscript{36} found that abnormalities in nerve excitability, specifically an increase in what they term “superexcitability,” or the period of time after the refractory period when it is much easier to generate an AP, of at least 15% that occurred early in treatment (prior to cycle 5) predicted the clinical outcome of moderate to severe paresthesia in 80% of patients. Collectively, these data indicate early or acute changes to Na\textsubscript{V} channels contribute to long-term CIPN in humans and may therefore represent relevant therapeutic molecular targets. But humans are not mice, so the question really becomes which human Na\textsubscript{V} channels are relevant?

To address this question, Argyriou et al.\textsuperscript{61} conducted a prospective multicenter study to identify single nucleotide polymorphisms in Na\textsubscript{V} genes that could confer susceptibility to oxaliplatin-induced peripheral neuropathy. They found two polymorphisms, one in Na\textsubscript{V}1.4, which is associated with increased incidence and severity of peripheral neuropathy, and the other in Na\textsubscript{V}1.8, which is associated with increased incidence. That Na\textsubscript{V}1.8 appears here is entirely congruent with the animal literature, while a role for Na\textsubscript{V}1.4 may be species specific.
Potassium channels

Biophysics

While NaV channels are widely considered to be key to CIPN, K+ channels are controversial even though they contribute to the hyperexcitability observed in other pain syndromes. In support, oxaliplatin application broadened the repolarization phase, and the AHP, and increased repetitive firing in rat peripheral myelinated nerve fibers, indicating that oxaliplatin-modulation of K+ channel inactivation was involved as channel inactivation shapes these electrical properties. Further supporting a role of K+ channels in CIPN, Benoit et al. found that oxaliplatin blocked K+ channels and shifted the voltage dependence of activation to more negative potentials (although it is three times less effective at blocking K+ than Na+ currents). Additionally, oxaliplatin can inhibit delayed rectifier K+ current amplitude but did not affect their activation and inactivation in NG-108-15 cells. In opposition, however, Adelsberger et al. found that oxaliplatin did not affect K+ currents in rat nerve preparations, while other studies observed that application of K+ channel blockers (4-AP, tetraethylammonium, and apamin) did not replicate the effects of oxaliplatin on nerve hyperexcitability and could still block K+ currents after administration of oxaliplatin. The biophysical data are equivocal with respect to supporting (or not) a role for K+ channels in CIPN.

Animal studies

Despite the somewhat ambiguous biophysical results, data from animal models support a role for K+ channels in CIPN. The discordant results may arise from the fact that K+ channels are among a highly diverse class of ion channels, and in neurons alone, there are at least five different subfamilies: voltage-gated (Kv), Ca2+ activated (KCa), inwardly rectifying (Kir), two-pore (K2P), and hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. In rats given paclitaxel, contrasting changes in expression of a variety of K+ channel genes from multiple families were observed; specifically, there were increases in mRNA expression coding for Kv1.2, Kv1.3, Kir3.1, and HCN1 channels along with reductions in Kir1.1, Kir3.4, and K2P1.1 mRNAs. Notably, these changes were accompanied by a significant increase in excitability (as measured by AP firing and rheobase) in medium and large but not small, diameter nociceptors. Oxaliplatin also induced changes in K+ channel mRNA in mouse DRGs, with a down regulation of TREK1, TREK2, TRAAK, and Kir1.1 and an increase in HCN1.

It is interesting that an increase in HCN1 mRNA appears to be a common feature across different classes of antineoplastics, suggesting that HCN1 channel regulation may represent a convergent pathway. HCN channels (HCN1-4) are activated by membrane hyperpolarization, are weakly selective for K+ over Na+, and are the basis for the pacemaker current, Ih, that contributes to the resting membrane potential and spontaneous firing in neurons. Mice treated with the non-isooform selective HCN channel blocker, ivabradine, did not experience oxaliplatin-mediated cold hypersensitivity and mechanical hyperalgesia (Figure 1). Given the mRNA results demonstrating an apparent bias for HCN1, it would be worth testing an HCN1-selective channel blocker to determine the degree to which a single HCN channel isoform drives CIPN pathophysiology and whether highly restricted targeting represents a viable therapeutic strategy; proof of in vivo target engagement could make use of appropriate gene deletion mouse models.

Other K+ channels have also been implicated in CIPN. In rats, GIRK1/Kir3.1 channels, which conduct an inward K+ current, are voltage independent, help maintain the resting membrane potential, and are involved in the morphine-induced relief of oxaliplatin-associated neuropathy. Interestingly, in a rat model of orofacial cold hyperalgesia induced by oxaliplatin, KCNQ (Kv7.1–7.5) channels (which help regulate neuronal excitability by contributing to the resting membrane potential) are key mediators of this hyperalgesia. When the KCNQ blocker linopirdine was injected into the orofacial region, it produced cold hyperalgesia (as demonstrated by reductions in total contact time with a cooling module); however, when the KCNQ activator retigabine was given to rats treated with oxaliplatin, there was a reduction in cold hyperalgesia. Finally, retigabine also partially restored nerve conduction properties and axon loss found in mice treated with cisplatin, indicating it could prevent CIPN. Although these data strongly implicate Kv7 channels as contributing to CIPN, such an interpretation is based on the assumption that the in vivo pharmacology is unambiguous (which is often not as “clean” as one would like) and should be correlated with corresponding changes in mRNA and/or protein levels in order to make a more compelling argument in support of such a role.

K2P potassium “leak” channels, yet another class of K+ channels involved in transducing noxious (i.e., painful) stimuli, conduct an outward K+ current that serves to hyperpolarize the resting membrane potential and help regulate neuronal excitability. TREK1, TREK2, and TRAAK are members of the K2P family and are thermosensitive channels that appear to play an important role in mediating cold hypersensitivity. TREK1 and TRAAK sense noxious cold temperatures, whereas TREK2 is involved in non-painful moderate cold sensation. As noted above, cold intolerance is a common feature in patients with CIPN. When TREK2 knock-out
mice were treated with oxaliplatin, they did not display chemotherapy-induced cool (i.e., at 20°C–25°C) hypersensitivity; in addition, wild-type mice treated with oxaliplatin, TREK2 mRNA was reduced by almost half in lumbar DRGs.64 Double (TREK1-TRAAK) and triple (TREK1-TREK2-TRAAK) knock-out mice did not display oxaliplatin-mediated cold (i.e., at 15°C) hypersensitivity62,64 emphasizing the roles of TREK1 and TRAAK channels involvement in CIPN at cold temperatures, as opposed to TREK2 involvement in CIPN at cool temperatures.

Another temperature-sensitive class of K⁺ channels that may contribute to cold intolerance in CIPN belongs to the “A-type” K⁺ channel family. Several different channel proteins (including Kv1.4, Kv3.4, Kv4.1–4.3) conduct a rapidly activating and inactivating A-type K⁺ current (Iₐ) which helps regulate resting membrane potential, current threshold for AP generation, and AP repolarization.112 Iₐ currents were significantly reduced at 24°C (by 32%), severely reduced at 15°C (by 74%), and almost eliminated at 10°C (by 88%).94 The inhibition of Iₐ can cause hyperexcitability of neurons leading to cold hypersensitivity because Iₐ essentially provides a brake for excitability; therefore, reduction of this current at cold temperatures releases that brake leading to membrane depolarization, which could then activate other channels.94 Whether A-type K⁺ channels contribute to CIPN is unknown; if they do, however, the participation of Kv4.2 is questionable as its expression in DRG neurons is negligible.113

**Human studies**

One human study investigated the role of the small conductance Ca²⁺-dependent potassium channel, SK3 (Kca2.3), in oxaliplatin-induced neurotoxicity.79 Kca2.3 is responsible for the AP AHP, thereby helping control neuronal excitability, and is located both in the spinal cord and in DRGs.114 Kca2.3 channels have a CAG motif that can repeat between 12 and 26 times115 and

---

**Figure 1.** Oxaliplatin-induced mechanical and cold hypersensitivity is reversed by ivabradine. (a) (Left) A single dose of oxaliplatin (6 mg/kg) causes a steady decrease in mechanical threshold over four days. On the fourth day, intraperitoneal administration of ivabradine (IVA; 5 mg/kg) or gabapentin (G.pen; 50 mg/kg) causes a significant increase in mechanical threshold when compared to vehicle-treated mice. (Right) Mean difference in mechanical threshold on Day 4 compared to pre-oxaliplatin levels for ivabradine, gabapentin, and vehicle-treated animals. Only ivabradine (open bar) returns the mechanical threshold fully to baseline levels. N = 10 for each group. (b) and (c) Number of jumps made by mice in response to a cold ramp (cooling from 20°C to 0°C at 2°C/min) before (basal) and four days after a single dose of oxaliplatin (Oxa; 6 mg/kg) with pre-administration (30 min) of vehicle (b) or ivabradine (c; 10 mg/kg). (d) Only the vehicle-treated group shows a significant difference in the number of jumps post-oxaliplatin (ΔAUC, difference in total number of jumps in response to temperature ramp), N = 10 for each group. Figure modified from Young et al.78 with permission.
is essential for channel tetramerization. The study by Basso et al.\textsuperscript{79} looked at sensory and motor nerve conduction and found that patients treated with oxaliplatin that had neuropathy also had increased nerve hyperexcitability (manifested as increased amplitude of the compound AP, increased discharge and variable intraburst frequency). Interestingly, this nerve hyperexcitability was related to the length of the CAG repeats found in SK3; specifically, patients with short CAG repeats (13–14) had increased nerve hyperexcitability.\textsuperscript{79} These results suggest that the shorter CAG region impairs the assembly or function of SK3 channels resulting in improper AP AHP formation, thereby leading to the increased discharge seen in these studies. In summary, chemotherapeutic agents affect nearly all subfamilies of the K\textsuperscript+ channel superfamily, suggesting that they are key elements in the development of CIPN, which could be considered legitimate molecular targets with respect to the development of new therapeutics.

**Calcium channels**

**Ca\textsuperscript{2+} signaling**

While calcium channels (Ca\textsubscript{V}) are known to be important contributors to pain signaling,\textsuperscript{116} their role in CIPN has not been studied as extensively as that for Na\textsubscript{V} and K\textsubscript{V} channels. Ca\textsubscript{V} can be divided into two groups, high voltage activated and low voltage activated based on the voltage at which they open.\textsuperscript{117} The Ca\textsubscript{V}1 (L-type) and Ca\textsubscript{V}2 (P/Q-, N-, and R-type) channels are members of the high-voltage activated group, and Ca\textsubscript{V}3 (T-type) channels are the sole members of the low-voltage activated group.\textsuperscript{118,119} In addition to the pore forming \alpha subunit, Ca\textsubscript{V} channels also consist of the \beta and \delta auxiliary subunits, which can enhance trafficking and channel expression as well as affect biophysical properties such as activation and inactivation.\textsuperscript{117} Initial studies into the role of Ca\textsubscript{V} channels in CIPN focused on changes in intracellular Ca\textsuperscript{2+} concentration, including influx through Ca\textsubscript{V} channels themselves as well as Ca\textsuperscript{2+} efflux from mitochondria and other intracellular Ca\textsuperscript{2+} stores.\textsuperscript{120} In general, intracellular Ca\textsuperscript{2+} regulation was shown to be disrupted after exposure to chemotherapy agents such as paclitaxel, vincristine, and oxaliplatin.\textsuperscript{12,15,20,121} Additionally, administration of intracellular Ca\textsuperscript{2+} chelators such as EGTA, TMB-8, and Quin-2 inhibited paclitaxel- and vincristine-induced mechano-allodynia and hyperalgesia in rats.\textsuperscript{120} Since chemotherapeutic agents affected intracellular Ca\textsuperscript{2+} to cause neuropathy, the next step was to determine if specific plasma membrane Ca\textsubscript{V} channels were involved.

Early research investigated global calcium entry via non-specific Ca\textsubscript{V} channels on the cell membrane.\textsuperscript{122} Cisplatin was shown to reduce peak and sustained Ca\textsuperscript{2+} currents in small diameter DRG neurons\textsuperscript{122}; in contrast, however, paclitaxel increased voltage-gated Ca\textsuperscript{2+} currents in small and medium diameter rat DRG neurons.\textsuperscript{49} These findings are important because small and medium diameter DRG neurons are responsible for conveying noxious sensory stimuli, suggesting these channels are important mediators of specific sensory abnormalities associated with CIPN. Recent studies have focused on the role of specific Ca\textsubscript{V} channels in the pathogenesis of CIPN. Short-term exposure of rat DRG to cisplatin resulted in a decrease in P/Q (i.e., Ca\textsubscript{V}2.1), L- and T-type (i.e., Ca\textsubscript{V}3.1–3.3), and Ca\textsuperscript{2+} currents but an increase in the N-type currents.\textsuperscript{55} N-type currents and protein levels are also increased after long-term exposure (24–48 h) to cisplatin.\textsuperscript{55} Interestingly, there are differences as to how N-type currents are upregulated at these two time points. Short-term increase in N-type currents occurs via protein kinase C (PKC), but long-term changes are mediated via CaMKII.\textsuperscript{55} Regulation of intracellular Ca\textsuperscript{2+} has important consequences on cell survival as nimodipine, an L-type (i.e., Ca\textsubscript{V}1.1–1.4) Ca\textsuperscript{2+} channel inhibitor, or \omega-conotoxin, an N-type (i.e., Ca\textsubscript{V}2.2) Ca\textsuperscript{2+} channel inhibitor, reduce cisplatin-induced DRG neuronal death in vitro.\textsuperscript{55,123}

**Animal models**

In animal models of CIPN, cisplatin administration increased protein, but not mRNA levels of the N-type Ca\textsubscript{V} channel, indicating post-translational modifications were responsible for the observed effects.\textsuperscript{55} Further supporting evidence for a role for N-type Ca\textsubscript{V} channels in CIPN can be found in studies with \omega-conotoxin, an N-type Ca\textsubscript{V} blocker that is clinically available as ziconotide (Prialt\textsuperscript{R}, Jazz Pharmaceuticals, Dublin, Ireland) and used in the treatment of severe chronic pain. When \omega-conotoxin is administered before cisplatin treatment, it prevented upregulation in N-type Ca\textsubscript{V} channel expression and the development of neuropathic pain\textsuperscript{55}; when administered after paclitaxel treatment, it reduced acute mechanical hyperalgesia and prevented the worsening of chronic pain.\textsuperscript{70} Likewise, Pha1b, a peptide toxin that blocks N-type Ca\textsubscript{V} channels (similar to \omega-conotoxin but with fewer side effects), can reduce paclitaxel-induced acute mechanical hyperalgesia and prevent the exacerbation of chronic pain in rats.\textsuperscript{70} T-type Ca\textsubscript{V} channels also play an important role in CIPN. When the T-type Ca\textsubscript{V}3.2 channel is knocked-down or pharmacologically blocked in a rat model of paclitaxel-induced peripheral neuropathy, antineoplastic-induced hyperalgesia is reversed.\textsuperscript{71} Similarly, if the anti-epileptic T-type Ca\textsubscript{V} channel blocker ethosuximide is administered to rats after paclitaxel (or vincristine) treatment, it can reverse the induced mechanical allodynia, hyperalgesia, and cold
Collectively, these results strongly suggest that changes in CaV2.2 and CaV3.2 expression or function contribute to CIPN.

A recent elegant study by Li et al. further suggests the importance of CaV3.2 channels in CIPN. Paclitaxel increased CaV3.2 channel expression in small DRG neurons that were positive for calcitonin gene-related peptide and isletcin B4, anatomical markers of nociceptive neurons. Following paclitaxel administration, acutely dissociated small diameter (<30 μm) DRG neurons were hyperexcitable (as measured by both spontaneous and depolarization-induced AP firing) compared to neurons obtained from vehicle-treated animals. These small diameter neurons also showed an increase in the T-type calcium current (as well as a shift in the activation curve to more negative potentials and a slowing of inactivation), contributing to increased Ca\(^{2+}\) entry. In vivo, paclitaxel-induced mechanical hypersensitivity was prevented by administration of the CaV3.2-specific inhibitor ML218 when administered to rats before and immediately after paclitaxel treatment, thereby providing additional support for a role of CaV3.2 in CIPN. Previously, Li et al. found that the toll-like receptor 4 (TLR4) contributed to paclitaxel-induced CIPN; consequently, they investigated its potential role in the increase in CaV3.2 expression and function. In the present study, the authors demonstrated that CaV3.2 and TLR4 co-localized to nociceptive neurons and can interact (as shown by co-immunoprecipitation). When a TLR4 inhibitor (TAK242) was administered to rats before and immediately after paclitaxel treatment, the results were similar to those obtained with ML218 described above, with a prevention of mechanical hypersensitivity. Collectively, these results suggest that paclitaxel acts via the TLR4 to upregulate CaV3.2 expression and function, which in turn results in spontaneous activity of DRG and neuropathic pain. Finally, they were able to replicate the in vitro results using freshly obtained (i.e., non-cadaveric) human DRG neurons, thereby providing the necessary translational link which could support pursuing novel treatment strategies. It is worth noting that the paclitaxel-induced hyperexcitability in DRG neurons decreased between post-treatment day 7 and day 14 (but not to baseline), suggesting that the initial hyperexcitability drives the development of CIPN, while the persistent excitability contributes to chronic neuropathic symptoms. If true, such a scenario has important implications with respect to the timing of any therapeutic intervention targeting CaV channel-dependent hyperexcitability (and potentially the other ion channels as well), and that such intervention should be initiated prior to the start of chemotherapy and then continue throughout; how long after the end of chemotherapy such treatment should continue would depend on the pharmacokinetic profile(s) of the given antineoplastic regimen.

As mentioned above, CaV channels have auxiliary β and δ subunits that are important in channel expression and function. Interestingly, antineoplastics also alter γδ subunit expression. Oxaliplatin, cisplatin, and paclitaxel increase γδ expression in DRG neurons, while paclitaxel increases γδ expression in the dorsal horn. Gabapentin, a clinically relevant anti-epileptic drug that binds to the CaV2.2 subunit, has been shown to have anti-hyperalgesic properties in CIPN. Thus, gabapentin has been shown to inhibit the paclitaxel-induced increase in Ca\(^{2+}\) currents in rat DRG neurons, and it normalizes the accompanying paclitaxel-induced increase in γδ expression. At the behavioral level, gabapentin reduced paclitaxel-, vincristine- and oxaliplatin-induced mecano-allodynia and hyperalgesia. As the γδ subunit appears to bind with CaV1 and CaV2, but not CaV3, these data strengthen the argument that CaV1 and CaV2 channels contribute to CIPN (but do not, of course, negate the results above implicating CaV3 channels as participants in CIPN pathophysiology).

**Human studies**

A small retrospective study of patients that underwent chemotherapy with oxaliplatin examined the relationship between CaV blocker-administration (presumably administered for their antihypertensive properties) and the incidence of CIPN. CaV blockers included any one of the following: amlodipine (n = 12), nifedipine (n = 5), azelnidipine (n = 2), diltiazem (n = 1), cilnidipine (n = 1), nilvadipine (n = 1), or amiodipine + nilvadipine (n = 1). Cumulative incidence curves were constructed whereby the probability of acute or chronic neuropathy was plotted against the cumulative dose of oxaliplatin, and the curves of the CaV blocker group were compared to the control group. The results indicated that patients who took a CaV blocker had a reduced incidence of acute, but not chronic, neuropathy. On the surface, these data are encouraging when contemplating strategies to prevent the development of CIPN, but there is significant heterogeneity among the hypertensives used; while the majority of the drugs tested were L-type (CaV1) CaV channel blockers, notable exceptions are amlodipine (N- and T-type, CaV2 and CaV3, respectively), benidipine (L-, N-, and T-type), cilnidipine (N-type), and nilvadipine (T- and L-type). Thus, drawing any firm conclusion as to which approach, if any, is the most viable is not possible; furthermore, the effect is only temporary. While this may have some value, it is by no means a panacea.

**TRP channels**

TRP channels are non-selective cation permeable channels that are highly permeable to Ca\(^{2+}\).
These channels are identified and classified into six subfamilies by their sequence homology to the trp gene originally found in Drosophila, and they included the following: (1) canonical (TRPC), (2) melastatin (TRPM), (3) vanilloid (TRPV), (4) ankyrin (TRPA), (5) mucolipin (TRPML), and (6) polycystin (TRPP). Of those six families, only three are associated with pain, TRPV, TRPA, and TRPM channels. Due to their permeability to Ca\(^{2+}\), these channels may also contribute to the Ca\(^{2+}\) disruption caused by chemotherapy agents. Furthermore, nine TRP channels contribute to thermoregulation and are activated by different temperatures, these channels are as follows: TRPV1, TRPV2, TRPV3, TRPV4, TRPM2, TRPM4, TRPM5, TRPM8, and TRPA1. Of the nine, only two are activated by cold (<18°C) temperatures, TRPA1 and TRPM8, which suggests that they could contribute to CIPN-associated cold hypersensitivity or cold-induced pain. Consequently, TRP channels have become an important research area for uncovering the etiology of CIPN.

**Animal studies**

A number of studies have investigated the effect of antineoplastic drugs on the gene and protein expression levels of TRP channels. In this context, oxaliplatin was found to increase the mRNA and protein levels of TRPM8 in rat DRGs and plantar skin samples. Furthermore, rats injected with oxaliplatin showed a peak increase in TRPM8 mRNA expression after three days which coincided with the peak of cold allodynia, suggesting an important mechanistic link between CIPN and ion channel regulation. Similarly, paclitaxel has also been shown to increase the mRNA and protein levels of TRPV1 in DRGs and the number of TRPV1-positive cells in DRG neurons.

Most of the studies on the role of TRP channels in CIPN utilize transgenic mice and channel agonists and antagonists to investigate the impact of chemotherapy agents. In one study, TRPA1 knock-out mice and the TRPA1 antagonist HC-030031 were used to block the rapid onset of oxaliplatin- and oxalate-induced cold hypersensitivity. In another study, HC-030031 reversed oxaliplatin-induced mechanical and cold hyperalgesia in rats, and TRPA1 knock-out mice lacked oxaliplatin-induced mechanical and cold hyperalgesia and displayed reduced cisplatin-induced mechanical allodynia.

A combination of TRPA1 and TRPV4 blockers (HC-030031 and HC-067047, respectively) completely inhibited paclitaxel-induced mechanical allodynia (which was only partially inhibited by each individual blocker). Further, paclitaxel-induced cold allodynia was markedly reduced in response to TRPA1 pharmacologic block or Trpa1 gene deletion. The TRPM8 blockers ABMP and TC-I 2014 also stopped oxaliplatin-induced cold allodynia, while the TRPV1 antagonists capsazepine and AMG9810 prevented paclitaxel-induced thermal hyperalgesia and mechanical hypersensitivity, respectively. Finally, Chen et al. utilized distinct blockers applied after paclitaxel administration to demonstrate a role for TRP channels in mechanical (TRPA1, TRPV4), and cold (TRPA1) allodynia, and heat hyperalgesia (TRPA1, TRPV4, TRPV1). Overall, the data from pre-clinical animal studies provide strong evidence in support of TRP channels contributing to CIPN.

**Human studies**

There are limited human data linking this class of ion channels to CIPN. In one study, Li et al. used cultured human DRG neurons and demonstrated that paclitaxel activates and sensitizes TRPV1 channel responses. In another clinical study, the TRPM8 activator menthol was used to assess the role of TRPM8 in CIPN. In this study, menthol was applied to the tongues of healthy subjects and cancer patients before and after chemotherapy treatment with oxaliplatin and determined the cold sensation detection threshold, which is the minimum concentration of menthol needed to produce a cold sensation. The investigators found that there was a decrease in the cold sensation detection threshold after the oxaliplatin chemotherapy treatment, demonstrating hypersensitivity to cold and suggesting a mechanistic role for TRPM8 in CIPN. Although there are strong indications from the pre-clinical animal literature that TRP channels contribute to CIPN, additional information is needed from human (or human tissue) studies to warrant pursuing this channel family as a therapeutic target in CIPN. If and when such data become available, TRP channels would clearly represent a novel target in the treatment of non-noxious temperature-dependent pain syndromes, including CIPN.

**Second messenger pathways**

The molecular mechanisms that underlie chemotherapy-induced changes in ion channel expression and function, and the resulting peripheral neuropathy, are poorly understood. Thus, even though platinum compounds as a class can produce CIPN, oxaliplatin, but neither cisplatin nor carboplatin, alters Na\(^{+}\) channel function, and this effect was recapitulated by oxalate but not by dichloro-diaminocyclohexane platinum. Such a mechanistic divergence within drug class suggests that additional pathways may contribute to the development and/or maintenance of CIPN for any given drug class. Indeed, there are indications that these agents may mediate their effects through other cellular signaling pathways including those that involve pro-inflammatory cytokines,
protein kinases, growth factors, and reactive oxygen species (ROS).\textsuperscript{15,73,121,142,143}

Importantly, these second messenger pathways can exert their effect by acting on ion channels.\textsuperscript{143–147} For example, protein kinases such as adenosine monophosphate-activated protein kinase (AMPK), mitogen-activated protein kinase, protein kinase A (PKA), and PKC have all been shown to be involved in CIPN.\textsuperscript{121,143,148} Concomitant administration of the oral hypoglycemic and AMPK activator metformin to mice with antineoplastics prevented development of mechanical hypersensitivity; such occlusion could result from either (1) mitogen-activated protein kinase-dependent changes in trafficking and/or phosphorylation or (2) AMPK-dependent phosphorylation of ion channels.\textsuperscript{142} In addition, PKA and PKC\textsubscript{e} antagonists can reduce paclitaxel (Taxol)-induced hyperalgesia,\textsuperscript{146} and it has been shown that these kinases can modulate ion channel function, including HCN and Na\textsubscript{V} channels.\textsuperscript{144,145} We will further discuss specific pathways and their role in CIPN with regard to ion channels below.

**Cytokines**

Cytokines can be released by both glia and neurons and are important in pain pathways.\textsuperscript{73} Chemotherapeutic agents induce the upregulation of macrophages leading to an elevated expression of pro-inflammatory cytokines, including TNF\textsubscript{z}, IL-1\textbeta, IL-6, and IL-8.\textsuperscript{149} TNF\textsubscript{z} and IL-1\textbeta can sensitize A and C fibers and increase AP discharge via increases in the density of Na\textsuperscript{+} and Ca\textsuperscript{2+} currents.\textsuperscript{149} Further support for a role for TNF\textsubscript{z} comes from the observations that TNF\textsubscript{z} mRNA is increased in a mouse model of vincristine-induced CIPN, while inhibition of TNF\textsubscript{z} activity using an anti-TNF\textsubscript{z} antibody prevented mechanical allodynia.\textsuperscript{150} In addition, TNF\textsubscript{z} has been shown to decrease Ca\textsuperscript{2+} currents and increase Na\textsuperscript{+} currents when directly applied to nociceptive DRG neurons.\textsuperscript{151} Finally, activation of TNF receptors increases Na\textsuperscript{+} currents in cultured rat DRG neurons.\textsuperscript{146}

With regard to chemotherapeutics, paclitaxel can induce expression of IL-1\textbeta, TNF\textsubscript{z}, and CD11b (a marker of immune cells/macrophages) mRNA in rat DRGs.\textsuperscript{152} Moreover, blocking IL-1\textbeta with a receptor antagonist or adding the anti-inflammatory cytokine IL-10 reversed and/or prevented paclitaxel-induced mechanical allodynia and decreased the expression of IL-1\textbeta, TNF\textsubscript{z}, and CD11b.\textsuperscript{152} Elsewhere it was demonstrated that paclitaxel-induced cold hyperalgesia depends on the chemokine (C-C motif) ligand 2 (CCL2) to activate the C-C chemokine receptor type 2 (CCR2), which in turn activates microglia,\textsuperscript{153} and activated microglia are principal participants in the development and maintenance of neuropathic pain.\textsuperscript{154} The link between microglia activation, cytokine release, and ion channel modulation is demonstrated by the observation that CCL2/CCR2 can activate PKC/NF\textkappaB which can, in turn, phosphorylate the Na\textsubscript{V}1.8 channel leading to increased current density in inflammation-induced neuropathic pain;\textsuperscript{155} such results are entirely consistent with a role of cytokine-dependent signaling in CIPN.\textsuperscript{156,157}

Another inflammatory cytokine that may also play a role in CIPN is IL-6, which is thought to be an important mediator in a wide variety of pathologic pain states.\textsuperscript{158} IL-6 levels were found to increase in macrophages near the sciatic nerve and DRGs of mice after vincristine treatment.\textsuperscript{159} The addition of an anti-IL-6 antibody, which prevents binding of IL-6 to its receptor (IL-6R), reduced mechanical allodynia after its development.\textsuperscript{159} A similar picture also emerged in IL-6 knockout mice treated with vincristine which displayed lower expression of mechanical allodynia.\textsuperscript{159} Deletion of glycoprotein 130 (GP130), a membrane protein, and IL-6 receptor that mediates the effect of the IL-6-IL-6R complex, led to a reduction in mechanical and thermal hypersensitivity as well as altered excitability and potassium conductance of nociceptors; specifically, there is increased mRNA levels of Kcna4 and A-type K\textsuperscript{+} channel current density connecting cytokine signaling with regulating K\textsuperscript{+} channel function in nociceptor excitability and pain.\textsuperscript{160} Finally, a breast cancer study that compared the expression of IL-6, and the soluble IL-6 receptor (sIL-6R) after chemotherapy found that painful CIPN was associated with elevated levels of IL-6/sIL-6R, and inversely correlated with QoL categories.\textsuperscript{161} The occurrence of painful CIPN symptoms and the reduced QoL were linked to the activation of GP130 by the IL-6 and sIL-6R complex\textsuperscript{161}, which further demonstrates its contribution to CIPN and potential as a therapeutic target.

**TRP channels and second messengers**

The channel family that has been best studied with regard to second messenger modulation by antineoplastics are TRP channels, thereby possibly providing an interesting link between chemotherapy agents, second messenger modulation, ion channels, and CIPN. For example, paclitaxel can sensitize TRPV1 responses to capsaicin when TRPV1 is co-expressed with TLR4, a receptor that when activated triggers downstream mechanisms that lead to secretion of pro-inflammatory cytokines in HEK293 cells, DRGs, and spinal neurons.\textsuperscript{125} Interestingly, adding a TLR4 agonist can mimic these results, and a TLR4 antagonist prevents the increase in the number of TRPV1-positive neurons induced by paclitaxel.\textsuperscript{125} In addition, TLR4 and TRPV1 are co-localized in rat and human DRG neurons.\textsuperscript{125} These results suggest that paclitaxel acts via the TLR4 receptor to sensitize TRPV1 leading to neuropathic pain.
TRPA1 channels are activated by oxidative stress and chemotherapeutics. Oxaliplatin can induce oxidative stress which results in the production of ROS; thus, TRPA1 may represent an important connection between oxidative stress, ROS, and CIPN. For example, oxidative stress agents such as 4-hydroxynonenal and hydrogen peroxide act via TRPA1 and can cause cold hyperalgesia, which mimics oxaliplatin-induced cold hyperalgesia. In addition, antioxidants such as acetyl-L-carnitine, α-lipoic acid, or vitamin C inhibit oxaliplatin-induced hyperalgesia. Similar results were observed with paclitaxel and TRPA1. Paclitaxel increased the production of ROS, which in turn sensitized TRPA1 channels, while ROS scavengers were shown to block paclitaxel-induced mechanical hyperalgesia.

Chen et al. conducted an elegant study piecing together a pathway from paclitaxel to neuropathic pain via the proteinase-activated receptor 2 (PAR2) pathway and TRP channels. It is known that mast cells release tryptase, an activator of PAR2, and a sign of inflammation, and PLC, PKC, and PKA are all downstream mediators of PAR2. PAR2 is expressed on DRG neurons, is co-expressed with TRPV1, TRPV4, and TRPA1 receptors, and can sensitize these channels via the PKA, PKC, and/or PLC pathway. Using a mouse model of paclitaxel-induced neuropathy, Chen et al. observed increased release of tryptase from mast cells and an antagonist to PAR2 blocked pain behaviors. This study also found that blocking PLC lessened thermal hypersensitivity, whereas PKCα blockers inhibited mechanical allodynia and heat hyperalgesia, and PKA inhibitors reversed mechanical allodynia, heat hyperalgesia, and cold hyperalgesia. Overall, Chen et al. found that mast cells release tryptase in response to paclitaxel which can then activate PAR2 initiating PKA, PKC, and PLC pathways which can then sensitize TRPV1, TRPV4, and TRPA1 leading to CIPN.

An important study linked Na⁺, Ca²⁺, and TRP channels in the pathway that contributes to oxaliplatin-induced cold hyperalgesia. After application of oxaliplatin or oxalate to rat DRGs, Kawashiri et al. observed cold hyperalgesia and a corresponding increase in TRPM8 mRNA, an increase in Ca²⁺ influx, and the translocation of nuclear factor of activated T-cell (NFAT) to the nucleus, all of which were blocked by L-type Ca²⁺ blockers (nifedipine or diltiazem) or the non-specific Na⁺ channel blocker mexiletine. These results suggest that: (1) oxaliplatin increases Na⁺ currents (see above); (2) the increase in Na⁺ current enhances local depolarization in the membrane potential, which facilitates opening of co-localized L-type channels; (3) the increase in Ca²⁺ channel opening results in increased Ca²⁺ influx; (4) the increase in intracellular Ca²⁺ activates NFAT, which then translocates to the nucleus; (5) nuclear NFAT upregulates the expression of TRPM8; and finally, (6) an increase in TRPM8 in the DRG results in cold hyperalgesia.

**Strategies to minimize CIPN**

Conceptually, there are two ways to mitigate the debilitating effects of CIPN, one is to prevent the neuropathy prior to its onset and the other is to treat the neuropathy after it has developed. To date, although animal models of pain have provided crucial mechanistic insights into the molecular mechanisms of CIPN, whether and how these results will translate into human clinical advances is not yet clear. In this context, several case studies, small trials, and retrospective studies have provided evidence suggesting potential therapeutic strategies for CIPN. One case study found that the Na⁺ blocker lacosamide completely relieved neuropathic pain in patients following chemotherapy associated with vincristine and cisplatin. In another study that utilized the anticonvulsant (and Ca V.2.0 channel blocker) pregabalin, patients displayed either complete resolution in their neuropathy or a significant reduction from Grade 3 to Grade 1. Furthermore, in a study involving 23 patients, it was demonstrated that oxaliplatin-induced peripheral neuropathy was reduced in 48% of patients when pregabalin is given after the establishment of CIPN. While encouraging, absent large, prospective randomized, controlled trials, these and other data “are insufficient to conclude that any of the purported chemoprotective agents... prevent or limit the neurotoxicity of platin drugs among human patients.”

There is still controversy about the efficacy of treatment options for CIPN when expanded to full Phase III randomized, double-blinded studies. For example, there have been contrasting reports on the impact of Ca²⁺/Mg²⁺ infusions on treatment efficacy. In an early retrospective, non-randomized study, oxaliplatin patients who were given Ca²⁺/Mg²⁺ infusions showed lower neuropathic intensity and recovered more rapidly from neuropathic pain. In contrast, in a placebo-controlled double-blinded prospective trial, there were indications that Ca²⁺/Mg²⁺ decreased the treatment efficacy of oxaliplatin, leading to early termination; however, a further analysis of the results after the fact demonstrated that there actually was no decrease in treatment efficacy. Another concurrent placebo-controlled randomized study was also terminated early because of the previous negative result; however, when the data were analyzed, the investigators observed a decrease in incidence of Grade 2 or greater sensory neuropathy. Despite a few positive outcomes, there are still concerns with the Ca²⁺/Mg²⁺ treatment strategy as a large double-blind, randomized study showed no effect on oxaliplatin-induced peripheral neuropathy. Similar to the Ca²⁺/Mg²⁺ treatment, other ion channel

---

**References:**

1. Chen et al. 75 conducted an elegant study piecing together a pathway from paclitaxel to neuropathic pain via the proteinase-activated receptor 2 (PAR2) pathway and TRP channels. 75 It is known that mast cells release tryptase, an activator of PAR2, and a sign of inflammation, and PLC, PKC, and PKA are all downstream mediators of PAR2. PAR2 is expressed on DRG neurons, is co-expressed with TRPV1, TRPV4, and TRPA1 receptors, and can sensitize these channels via the PKA, PKC, and/or PLC pathway. Using a mouse model of paclitaxel-induced neuropathy, Chen et al. observed increased release of tryptase from mast cells and an antagonist to PAR2 blocked pain behaviors. This study also found that blocking PLC lessened thermal hypersensitivity, whereas PKCα blockers inhibited mechanical allodynia and heat hyperalgesia, and PKA inhibitors reversed mechanical allodynia, heat hyperalgesia, and cold hyperalgesia. Overall, Chen et al. found that mast cells release tryptase in response to paclitaxel which can then activate PAR2 initiating PKA, PKC, and PLC pathways which can then sensitize TRPV1, TRPV4, and TRPA1 leading to CIPN.

2. An important study linked Na⁺, Ca²⁺, and TRP channels in the pathway that contributes to oxaliplatin-induced cold hyperalgesia. After application of oxaliplatin or oxalate to rat DRGs, Kawashiri et al. observed cold hyperalgesia and a corresponding increase in TRPM8 mRNA, an increase in Ca²⁺ influx, and the translocation of nuclear factor of activated T-cell (NFAT) to the nucleus, all of which were blocked by L-type Ca²⁺ blockers (nifedipine or diltiazem) or the non-specific Na⁺ channel blocker mexiletine. These results suggest that: (1) oxaliplatin increases Na⁺ currents (see above); (2) the increase in Na⁺ current enhances local depolarization in the membrane potential, which facilitates opening of co-localized L-type channels; (3) the increase in Ca²⁺ channel opening results in increased Ca²⁺ influx; (4) the increase in intracellular Ca²⁺ activates NFAT, which then translocates to the nucleus; (5) nuclear NFAT upregulates the expression of TRPM8; and finally, (6) an increase in TRPM8 in the DRG results in cold hyperalgesia.

3. **Strategies to minimize CIPN**

   Conceptually, there are two ways to mitigate the debilitating effects of CIPN, one is to prevent the neuropathy prior to its onset and the other is to treat the neuropathy after it has developed. To date, although animal models of pain have provided crucial mechanistic insights into the molecular mechanisms of CIPN, whether and how these results will translate into human clinical advances is not yet clear. In this context, several case studies, small trials, and retrospective studies have provided evidence suggesting potential therapeutic strategies for CIPN. One case study found that the Na⁺ blocker lacosamide completely relieved neuropathic pain in patients following chemotherapy associated with vincristine and cisplatin. In another study that utilized the anticonvulsant (and Ca V.2.0 channel blocker) pregabalin, patients displayed either complete resolution in their neuropathy or a significant reduction from Grade 3 to Grade 1. Furthermore, in a study involving 23 patients, it was demonstrated that oxaliplatin-induced peripheral neuropathy was reduced in 48% of patients when pregabalin is given after the establishment of CIPN. While encouraging, absent large, prospective randomized, controlled trials, these and other data “are insufficient to conclude that any of the purported chemoprotective agents... prevent or limit the neurotoxicity of platin drugs among human patients.”

   There is still controversy about the efficacy of treatment options for CIPN when expanded to full Phase III randomized, double-blinded studies. For example, there have been contrasting reports on the impact of Ca²⁺/Mg²⁺ infusions on treatment efficacy. In an early retrospective, non-randomized study, oxaliplatin patients who were given Ca²⁺/Mg²⁺ infusions showed lower neuropathic intensity and recovered more rapidly from neuropathic pain. In contrast, in a placebo-controlled double-blinded prospective trial, there were indications that Ca²⁺/Mg²⁺ decreased the treatment efficacy of oxaliplatin, leading to early termination; however, a further analysis of the results after the fact demonstrated that there actually was no decrease in treatment efficacy. Another concurrent placebo-controlled randomized study was also terminated early because of the previous negative result; however, when the data were analyzed, the investigators observed a decrease in incidence of Grade 2 or greater sensory neuropathy. Despite a few positive outcomes, there are still concerns with the Ca²⁺/Mg²⁺ treatment strategy as a large double-blind, randomized study showed no effect on oxaliplatin-induced peripheral neuropathy. Similar to the Ca²⁺/Mg²⁺ treatment, other ion channel
modulators including carbamazepine, a Na<sub>\text{V}</sub> blocker, and gabapentin, a Ca<sub>\text{V}</sub> channel blocker, also showed promise in some trials<sup>173</sup> but not in others.<sup>173,188</sup> Anti-oxidants as treatments have also demonstrated some initial positive results.<sup>170,173,189</sup> Amifostine, a free radical scavenger, showed some benefits in preliminary trials with small, but significant, reductions in neuropathy<sup>190,191</sup> but were associated with side effects,<sup>190</sup> and other studies showed a lack of effect.<sup>180,192,193</sup> Thus its use is not recommended. The anti-oxidant, glutathione, also revealed mixed results. There were small randomized trials that showed some benefit<sup>194–197</sup>; however, a larger placebo-controlled study did not.<sup>198</sup> Another anti-oxidant and modulator of NGF, acetyl-L-carnitine, had similar results, positive findings in small preliminary studies<sup>173,199</sup> which were not replicated in a larger double-blind placebo-controlled study.<sup>200</sup> Early promising results could not be replicated in subsequent larger studies is not uncommon,<sup>201</sup> and the lack of reproducibility highlights the need to conduct large properly designed studies in the first place.<sup>202–204</sup>

One treatment strategy recently made the transition from positive results in a preliminary trial to a large placebo-controlled trial.<sup>205</sup> Omega-3 fatty acids prevented paclitaxel-induced peripheral neuropathy in a small trial that included patients suffering from breast cancer.<sup>206</sup> Similar results were observed in a recent randomized, double-blind, placebo-controlled study on the effects of n-3 polyunsaturated fatty acids on oxaliplatin-induced peripheral neuropathy in patients with colon cancer. This study also showed a reduction in the incidence and severity of the neuropathy,<sup>205</sup> indicating polyunsaturated fatty acids warrant further investigation.

In 2014, the American Society of Clinical Oncology Clinical Practice published guidelines regarding the prevention and management of CIPN (Table 3)<sup>186,207</sup>; they could not recommend a relevant drug option for the prevention of CIPN due to the lack of high-quality and consistent evidence for the distinct interventions.<sup>186</sup> However, duloxetine, a serotonin and norepinephrine dual re-uptake inhibitor, was their only treatment recommendation due to a positive Phase III clinical trial; it was a qualified recommendation, however, as duloxetine is not universally effective in that it was more effective

| Proposed treatment                  | Strength of evidence | Recommendation       | Benefit(s)     | Harm(s)<sup>a</sup> |
|-------------------------------------|----------------------|----------------------|----------------|---------------------|
| Acetyl-L-carnitine                  | Low                  | Inconclusive         | Low            | Moderate            |
| Duloxetine                          | Intermediate         | Moderate for         | Intermediate   | Low                 |
| Gabapentin                          | Intermediate         | Inconclusive         | Low            | Low                 |
| Lamotrigine                         | Intermediate         | Moderate against     | None demonstrated| Low                 |
| Nortriptyline/amitriptyline         | Intermediate         | Inconclusive         | Low            | Low                 |
| Topical amitriptyline, ketamine, ± Baclofen | Intermediate     | Inconclusive         | Moderate        | Low                 |

Source: Table modified from Hershman et al.<sup>186</sup>

<sup>a</sup>“Harms” were identified by the Clinical Practice Guideline Committee based on the specific clinical trials identified in the review and not on any other evaluations of the safety of those treatments. These recommendations are separate and distinct from the ASCO practice guidelines for the management of chronic pain in survivors of adult cancers.<sup>202</sup>
against oxaliplatin-induced CIPN than that induced by taxanes.\textsuperscript{17,186} While none of the current published studies have provided an appropriate therapy, there are currently over 30 clinical trials currently active regarding CIPN treatments which could provide promising results in the future.\textsuperscript{208}

So the important question is why is there a lack of high-quality consistent evidence? The lack of progress may be due to the fact that most of the studies that show positive results are generally associated with a small sample size, are un-blinded, or had no placebo controls, and the negative side effects of the agents are generally not reported.\textsuperscript{17,170,186} Furthermore, there is also a lack of a universally agreed upon method to assess the occurrence of CIPN in clinical trials. Current CIPN assessment methods include physical exams, patient questionnaires, neuropathy scales and scores, nerve conduction studies, and quantitative sensory testing.\textsuperscript{172} In addition, there are no standardized approaches to assess the efficacy of these drugs, with studies reporting a combination of symptom scores, clinical assessments, nerve conduction data, and results from quantitative sensory testing.\textsuperscript{172} Therefore, it would be important to create a standardized method for the assessment of CIPN occurrence, as well as assessing the efficacy of the agent tested, in order to identify successful strategies for the prevention and/or treatment of CIPN.\textsuperscript{209}

**Conclusion/future directions**

This review has highlighted data from animal and human studies implicating changes in primary afferent excitability resulting from alterations in ion channel expression and function as a common mechanism leading to the development of CIPN. While mechanisms have been invoked (Figure 2),\textsuperscript{73,156,210} there are abundant data implicating ion channels (Tables 1 and 2) and second messengers such as cytokines in the development of CIPN. This is not an unexpected finding as changes in neuronal excitability appear to be a common feature of other neuropathic pain disorders including painful diabetic neuropathy and those associated with peripheral nerve injury.\textsuperscript{47,212,213}

While animal studies have provided many exciting positive results (reviewed by Hama and Takamatsu\textsuperscript{214}), the heralded promise of those results has not translated into positive results in human clinical trials. Is it possible that we have been focusing on the wrong targets? Conditional gene deletion (“knockout”) strategies to study the role of various proteins in neuropathic pain have been successfully employed\textsuperscript{215–223} all of which appear to confirm them as reasonable targets. One problem with the gene deletion approach, however, is compensatory up- or down-regulation of other channels or signaling cascades, resulting in cellular and/or synaptic homeostasis.\textsuperscript{224–227} As previously noted, another important consideration when interpreting gene deletion studies (at least as they relate to pain) is that the role of a given protein, be it an ion channel or enzyme, in pathological-mediated neuropathic pain may not be equivalent to measuring the initiation/development of such pain when it is constitutively absent.\textsuperscript{47} While there are important similarities in changes in ion channel protein expression between rodent and human sensory neurons, there may be just as important differences. These differences may account for the divergent results obtained with in vivo models examining new therapeutics for the treatment of neuropathic pain (see e.g., Jarvis et al.\textsuperscript{227} and Ziegler et al.\textsuperscript{228})

The failure to translate the pre-clinical results into effective treatment strategies is multifactorial, with numerous potential solutions, including the development of more realistic pre-clinical models,\textsuperscript{47} including the use of a non-human primate (NHP) model.\textsuperscript{214,229} In theory, an NHP-model might be an improvement over widely used rodent models, but the use of NHPs has been challenged on ethical and scientific grounds.\textsuperscript{230} A viable and rapidly developing approach is to use a model that avoids the use of non-human tissues and which instead incorporates sensory neurons derived from human stem cells.\textsuperscript{231,232}

Human stem cells, both embryonic stem cells or induced pluripotent, have been used as models of neurodegenerative disease and have provided promising results.\textsuperscript{233} Pluripotent stem cells have also been suggested as an approach for studying ion channelopathies.\textsuperscript{234} To date, though, there are few studies using human stem cells as a research paradigm for studying pain-related phenomena.\textsuperscript{17,233,236} One such study found human fibroblast-derived nociceptors had functional TRPV1, TRPA1, and TRPM8 channels, generated TTX-resistant action potentials and phasic firing patterns characteristic of nociceptors, and when exposed to oxaliplatin, demonstrated sensitization of TRPV1.\textsuperscript{236} Elsewhere, Wheeler et al.\textsuperscript{233} successfully modeled CIPN with human-induced pluripotent stem cells. They found when cells were treated with paclitaxel, vincristine, or cisplatin, there were morphological differences in neurites including changes in outgrowth, process length, and outgrowth intensity.\textsuperscript{233} The authors also knocked down the TUBB2A gene (whose expression has been shown to be associated with reduced risk of paclitaxel-induced neuropathy) in these cells and observed a reduction in neurite outgrowth after adding paclitaxel, suggesting an increased sensitivity to this chemotherapeutic agent.\textsuperscript{233} Overall, these studies indicate that human stem cells could be a realistic pre-clinical human model for the study of CIPN.

At the in vivo level, neuroimaging techniques, including magnetic resonance imaging or positron emission tomography, can be used to investigate CIPN.\textsuperscript{236–238}
These techniques have been used to study pain across species, from rodent to humans, which makes it a particularly strong tool. Advantages of neuroimaging included the following: (1) the ability to follow the progression of the disease, (2) the ability monitor the network (rather than self-reported) response to various treatment strategies, and (3) utility in both pre-clinical and clinical research, thereby allowing direct correlation across in vivo models.237,239 Neuroimaging can even be informative at the molecular level, with the ability to image receptor distribution as well as ligand: receptor interactions and the corresponding signal transduction pathways.237 Newer techniques using miniature optical imaging systems that can be attached to the head of awake, freely moving rodents have been developed, and this technology avoids the confounding effects of sedation and restraints routinely employed during imaging systems that can be attached to the head of awake, freely moving rodents have been developed, and this technology avoids the confounding effects of sedation and restraints routinely employed during imaging.211 While these techniques have not been used to study CIPN, they could be an interesting new approach since they have been used successfully to study other pain syndromes.

In summary, CIPN is a pervasive condition that at present has no prevention and only one mildly recommended treatment strategy.186 Despite the diversity of antineoplastic agents and their therapeutic mechanisms of action, one common theme contributing to the mutual pathophysiology of CIPN is their ability to modulate ion channel expression and function, either directly or through second messengers and inflammatory cytokines. Bridging the gap between the results obtained using the current pre-clinical models with those obtained thus far in humans will be necessary if we are to find effective strategies to treat, or even better, prevent, CIPN.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Tri-Institutional Stem Cell Initiative grant no. 2016-025 (to PAG) and funds from the Weill Cornell Medical Center – Department of Anesthesiology.

References
1. Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 2016; 3: 524–548.
2. Bates D and Eastman A. Microtubule destabilising agents: far more than just antimitotic anticancer drugs. Br J Clin Pharmacol 2017; 83: 255–268.
3. Fernandes R, Mazzarello S, Hutton B, et al. A systematic review of the incidence and risk factors for taxane acute pain syndrome in patients receiving taxane-based chemotherapy for prostate cancer. Clin Genitourin Cancer 2017; 15: 1–6.
4. Gu G, Dustin D and Fuqua SA. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment. Curr Opin Pharmacol 2016; 31: 97–103.
5. Michels S and Wolf J. Stratified treatment in lung cancer. Oncol Res Treat 2016; 39: 760–766.
6. van Vuuren RJ, Visagie MH, Theron AE, et al. Antimitotic drugs in the treatment of cancer. Cancer Chemother Pharmacol 2015; 76: 1101–1112.
7. Bleyer A, Ferrari A, Whelan J, et al. Global assessment of cancer incidence and survival in adolescents and young adults. Pediatr Blood Cancer. Epub ahead of print 28 February 2017. DOI: 10.1002/pbc.26497.
8. Ewertz M, Qvortrup C and Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol 2015; 54: 587–591.
9. Grisold W, Cavaletti G and Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 2012; 14: iv54–55.
10. Miltenburg NC and Boogerd W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev 2014; 40: 872–882.
11. Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 2013; 63: 419–437.
12. Cavaletti G, Frigeni B, Lanzani F, et al. The total neuropathy score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 2007; 12: 210–215.
13. Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 2014; 155: 2461–2470.
14. Fallon MT. Neuropathic pain in cancer. Br J Anaesth 2013; 111: 105–111.
15. Carozzi VA, Canta A and Chiorazzi A. Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett 2015; 596: 90–107.
16. Lee JJ and Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006; 24: 1633–1642.
17. Brewer JR, Morrison G, Dolan ME, et al. Chemotherapy-induced peripheral neuropathy: current status and progress. Gynecol Oncol 2016; 140: 176–183.
18. Hershman DL, Weimer LH, Wang A, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 2011; 125: 767–774.
19. Pignata S, De Placido S, Biamonte R, et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. *BMC Cancer* 2006; 6: 5.

20. Osmani K, Vignes S, Aissi M, et al. Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation. *J Neurol* 2012; 259: 1936–1943.

21. Andersen KG, Jensen MB, Kehlet H, et al. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide. *Acta Oncol* 2012; 51: 1036–1044.

22. Gill JS and Windebank AJ. Cisplatin-induced apoposis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. *J Clin Invest* 1998; 101: 2842–2850.

23. Ta LE, Espeset L, Podratz J, et al. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. *Neurotoxicology* 2006; 27: 992–1002.

24. McWhinney SR, Goldberg RM and McLeod HL. Platinum neurotoxicity pharmacogenetics. *Mol Cancer Ther* 2009; 8: 10–16.

25. Cavaletti G, Marzorati L, Bogliun G, et al. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. *Cancer* 1992; 69: 203–207.

26. von Schlippe M, Fowler CJ and Harland SJ. Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis. *Br J Cancer* 2001; 85: 823–826.

27. Brouwers EE, Huijema AD, Beijnen JH, et al. Long-term platinum retention after treatment with cisplatin and oxaliplatin. *BMC Clin Pharmacol* 2008; 8: 7.

28. Sprauten M, Darrah TH, Peterson DR, et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer. *J Clin Oncol* 2012; 30: 300–307.

29. Strumberg D, Brugge S, Korn MW, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. *Ann Oncol* 2002; 13: 229–236.

30. Petrioli R, Pascucci A, Francini E, et al. Neurotoxicity of FOLFIRI-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. *Cancer Chemother Pharmacol* 2008; 61: 105–111.

31. Pietrangeli A, Leandri M, Terzoli E, et al. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. *Eur Neurol* 2006; 56: 13–16.

32. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. *J Clin Oncol* 2000; 18: 2938–2947.

33. Baek KK, Lee J, Park SH, et al. Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer. *Cancer Res Treat* 2010; 42: 185–190.

34. Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. *Cancer* 2013; 119: 438–444.

35. Grothey A. Oxaliplatin-safety profile: neurotoxicity. *Semin Oncol* 2003; 30: 5–13.

36. Park SB, Lin CS, Krishnan AV, et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. *Brain* 2009; 132: 2712–2723.

37. Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. *J Clin Oncol* 2002; 20: 1767–1774.

38. Weichhardt A, Wells K and Messersmith W. Oxaliplatin-induced neuropathy in colorectal cancer. *J Oncol* 2011; 2011: 201593.

39. Brouwers EE, Huijema AD, Boogerd W, et al. Persistent neuropathy after treatment with cisplatin and oxaliplatin. *Acta Oncol* 2009; 48: 832–841.

40. Park SB, Lin CS, Krishnan AV, et al. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. *Oncologist* 2011; 16: 708–716.

41. Bennett BK, Park SB, Lin CS, et al. Impact of oxaliplatin-induced neuropathy: a patient perspective. *Support Care Cancer* 2012; 20: 2959–2967.

42. Mols F, Beijers T, Lemmens V, et al. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. *J Clin Oncol* 2013; 31: 2699–2707.

43. Haim N, Epelbaum R, Ben-Shahar M, et al. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. *Cancer* 1994; 73: 2515–2519.

44. Verstappen CC, Koeppen S, Heimans JJ, et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. *Neurology* 2005; 64: 1076–1077.

45. Moser EC, Noordijk EM, Carde P, et al. Late non-neoplastic events in patients with aggressive non-Hodgkin’s lymphoma in four randomized European organisation for research and treatment of cancer trials. *Clin Lymphoma Myeloma* 2005; 6: 122–130.

46. Ramchandren S, Leonard M, Mody RJ, et al. Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. *J Peripher Nerv Syst* 2009; 14: 184–189.

47. Tibbs GR, Posson DJ and Goldstein PA. Voltage-gated ion channels in the PNS: novel therapies for neuropathic pain? *Trends Pharmacol Sci* 2016; 37: 522–542.

48. Zhang H and Dougherty PM. Enhanced excitability of primary sensory neurons and altered gene expression of neuronal ion channels in dorsal root ganglion in paclitaxel-induced peripheral neuropathy. *Anesthesiology* 2014; 120: 1463–1475.

49. Kawakami K, Chiba T, Katagiri N, et al. Paclitaxel increases high voltage-dependent calcium channel current in dorsal root ganglion neurons of the rat. *J Pharmacol Sci* 2012; 120: 187–195.

50. Gauchan P, Andoh T, Ikeda K, et al. Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of
51. Matsumoto M, Inoue M, Hald A, et al. Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin. *J Pharmacol Exp Ther* 2006; 318: 735–740.

52. Xiao W, Boroujerdi A, Bennett GJ, et al. Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. *Neuroscience* 2007; 144: 714–720.

53. Hara T, Chiba T, Abe K, et al. Effect of paclitaxel on transient receptor potential vanilloid 1 in rat dorsal root ganglion. *Pain* 2013; 154: 882–889.

54. Li Y, Tatsui CE, Rhines LD, et al. Dorsal root ganglion neurons become hyperexcitable and increase expression of voltage-gated T-type calcium channels (Cav3.2) in paclitaxel-induced peripheral neuropathy. *Pain* 2017; 158: 417–429.

55. Leo M, Schmitt LI, Erkel M, et al. Cisplatin-induced neuropathic pain is mediated by upregulation of N-type voltage-gated calcium channels in dorsal root ganglion neurons. *Exp Neurol* 2016; 288: 62–74.

56. Sittl R, Lampert A, Huth T, et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Nav1.6-resurgent and persistent current. *Proc Natl Acad Sci U S A* 2012; 109: 6704–6709.

57. Kanbara T, Nakamura A, Shibasaki M, et al. Morphine and oxycodone, but not fentanyl, exhibit antinoceptive effects mediated by G-protein inwardly rectifying potassium (GIRK) channels in an oxaliplatin-induced neuropathy rat model. *Neurosci Lett* 2014; 580: 119–124.

58. Gauchan P, Andoh T, Kato A, et al. Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice. *Neurosci Lett* 2009; 458: 93–95.

59. Kawashiri T, Egashira N, Kurobe K, et al. CAG motif of SK3 gene is associated with acute oxaliplatin-induced peripheral neuropathy. *Exp Neurol* 2014; 255: 223–227.

60. Mizoguchi S, Andoh T, Yakura T, et al. Involvement of c-Myc-mediated transient receptor potential melastatin 8 expression in oxaliplatin-induced cold allodynia in mice. *Mol Pain* 2012; 8: 7.

61. Miozgochi S, Andoh T, Yakura T, et al. Involvement of c-Myc-mediated transient receptor potential melastatin 8 expression in oxaliplatin-induced cold allodynia in mice. *Pharmacol Rep* 2016; 68: 645–648.

62. Argyriou AA, Cavaletti G, Antonacopoulos L, et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. *Cancer* 2013; 119: 3570–3577.

63. Descoeur J, Pereira V, Pizzocaro A, et al. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. *EMBO Mol Med* 2011; 3: 266–278.

64. Ghelardini C, Desaphy JF, Muraglia M, et al. Effects of a new potent analog of tcaoinide on hNav1.7 sodium channels and in vivo neuropathic pain models. *Neuroscience* 2010; 169: 863–873.

65. Pereira V, Busserolles J, Christin M, et al. Role of the TREK2 potassium channel in cold and warm thermosensation and in pain perception. *Pain* 2014; 155: 2534–2544.

66. Wu SN, Chen BS, Wu YH, et al. The mechanism of the actions of oxaliplatin on ion currents and action potentials in differentiated NG108-15 neuronal cells. *Neurotoxicology* 2009; 30: 677–685.

67. Abd-Elsayed AA, Ikeda R, Jia Z, et al. KCNQ channels in nociceptive cold-sensing trigeminal ganglion neurons as therapeutic targets for treating orofacial cold hyperalgesia. *Mol Pain* 2015; 11: 45.

68. Nodera H, Spieker A, Sung M, et al. Neuroprotective effects of Kv7 channel agonist, retigabine, for cisplatin-induced peripheral neuropathy. *Neurosci Lett* 2011; 505: 223–227.

69. Nieto FR, Entrena JM, Cendan CM, et al. Tetrodotoxin inhibits the development and expression of neuropathic pain induced by paclitaxel in mice. *Pain* 2008; 137: 520–531.

70. Rigo FK, Dalmolin GD, Trevisan G, et al. Effect of omega-conotoxin MVIIA and Phalphalbeta on paclitaxel-induced acute and chronic pain. *Pharmacol Biochem Behav* 2013; 114–115: 16–22.

71. Okubo K, Takahashi T, Sekiguchi F, et al. Inhibition of T-type calcium channels and hydrogen sulfide-forming enzyme reverses paclitaxel-evoked neuropathic hyperalgesia in rats. *Neuroscience* 2011; 188: 148–156.

72. Flatters SJ and Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. *Pain* 2004; 109: 150–161.

73. Boyette-Davis JA, Walters ET and Dougherty PM. Mechanisms involved in the development of chemotherapy-induced neuropathy. *Pain Manag* 2015; 5: 285–296.

74. Materazzi S, Fusi C, Benemèi S, et al. TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism. *Pflugers Arch* 2012; 463: 561–569.

75. Chen Y, Yang C and Wang ZJ. Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain. *Neuroscience* 2011; 193: 440–451.

76. Nassini R, Gees M, Harrison S, et al. Oxiplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. *Pain* 2011; 152: 1621–1631.

77. Minett MS, Falk S, Santana-Varela S, et al. Pain without nociceptors? *Mol Pain* 2014; 6: 301–312.

78. Young GT, Emery EC, Mooney ER, et al. Inflammatory and neuropathic pain are rapidly suppressed by peripheral block of hyperpolarisation-activated cyclic nucleotide-gated ion channels. *Pain* 2013; 155: 1708–1719.

79. Basso M, Modoni A, Spada D, et al. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity. *Cancer Chemother Pharmacol* 2011; 67: 1179–1187.

80. Zhao M, Isami K, Nakamura S, et al. Acute cold hyperalgesia and TRPM8 overexpression in rats. *Mol Pain* 2014; 155: 780–788.
81. Joshi SK, Mikusa JP, Hernandez G, et al. Involvement of the TTX-resistant sodium channel Nav 1.8 in inflammatory and neuropathic, but not post-operative, pain states. *Pain* 2006; 123: 75–82.
82. Moalem G and Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. *Brain Res Rev* 2006; 51: 240–264.
83. Thacker MA, Clark AK, Marchand F, et al. Pathophysiology of peripheral neuropathic pain: immune cells and molecules. *Anest Analg* 2007; 105: 838–847.
84. Uceyler N, Schafers M and Sommer C. Mode of action of cytokines on nociceptive neurons. *Exp Brain Res* 2009; 196: 67–78.
85. Vezzani A and Viviani B. Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. *Neuropharmacology* 2015; 96: 70–82.
86. Bean BP. The action potential in mammalian central neurons. *Nat Rev Neurosci* 2007; 8: 451–465.
87. Adelsberger H, Quasthoff S, Grosskreutz J, et al. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. *Eur J Pharmacol* 2000; 406: 25–32.
88. Catterall WA, Goldin AL and Waxman SG. International union of pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. *Pharmacol Rev* 2005; 57: 397–409.
89. Grolleau F, Gamelin L, Boisdron-Celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. *J Neurophysiol* 2001; 85: 2293–2297.
90. Webster RG, Brain KL, Wilson RH, et al. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. *Br J Pharmacol* 2005; 146: 1027–1039.
91. Benoit E, Brienza S and Dubois JM. Oxaliplatin, an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons. *Gen Physiol Biophys* 2006; 25: 263–276.
92. Sakurai M, Egashira N, Kawashiri T, et al. Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia. *Pain* 2009; 147: 165–174.
93. Foulkes T and Wood J. Mechanisms of cold pain. *Channels* 2014; 1: 154–160.
94. Sarria I, Ling J and Gu JG. Thermal sensitivity of voltage-gated Na+ channels and A-type K+ channels contributes to somatosensory neuron excitability at cooling temperatures. *J Neurochem* 2012; 122: 1145–1154.
95. Zimmermann K, Leffler A, Babes A, et al. Sensory neuron sodium channel Nav1.8 is essential for pain at low temperatures. *Nature* 2007; 447: 855–858.
96. Krishnan AV, Goldstein D, Friedlander M, et al. Oxaliplatin and axonal Na+ channel function in vivo. *Clin Cancer Res* 2006; 12: 4481–4484.
97. Busserolles J, Tsantoulas C, Eschalier A, et al. Potassium channels in neuropathic pain: advances, challenges, and emerging ideas. *Pain* 2016; 157: S7–S14.
98. Kagiava A, Tsingotjidou A, Emmanouilides C, et al. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. *Neurotoxicology* 2008; 29: 1100–1106.
99. Lujan R. Organisation of potassium channels on the neuronal surface. *J Chem Neuroanat* 2010; 40: 1–20.
100. Biel M, Wahl-Schott C, Michalakis S, et al. Hyperpolarization-activated cation channels: from genes to function. *Physiol Rev* 2009; 89: 847–885.
101. Ludwig A, Zong X, Jeglitsch M, et al. A family of hyperpolarization-activated mammalian cation channels. *Nature* 1998; 393: 587–591.
102. Santoro B, Liu DT, Yao H, et al. Identification of a gene encoding a hyperpolarization-activated pacemaker channel of brain. *Cell* 1998; 93: 717–729.
103. Wahl-Schott C and Biel M. HCN channels: structure, cellular regulation and physiological function. *Cell Mol Life Sci* 2009; 66: 470–494.
104. Del Lungo M, Melchiorre M, Guandalini L, et al. Novel blockers of hyperpolarization-activated current with isoform selectivity in recombinant cells and native tissue. *Br J Pharmacol* 2012; 166: 602–616.
105. McClure KJ, Maher M, Wu N, et al. Discovery of a novel series of selective HCN1 blockers. *Bioorg Med Chem Lett* 2011; 21: 5197–5201.
106. Melchiorre M, Del Lungo M, Guandalini L, et al. Design, synthesis, and preliminary biological evaluation of new isoform-selective f-current blockers. *J Med Chem* 2010; 53: 6773–6777.
107. Tibbs GR, Rowley TJ, Sanford RL, et al. HCN1 channels as targets for anesthetic and nonanesthetic propofol analogs in the amelioration of mechanical and thermal hyperalgesia in a mouse model of neuropathic pain. *J Pharmacol Exp Ther* 2013; 345: 363–373.
108. Hibino H, Inanobe A, Furutani K, et al. Inwardly rectifying potassium channels: their structure, function, and physiological roles. *Physiol Rev* 2010; 90: 291–366.
109. Brown DA and Passmore GM. Neural KCNQ (Kv7) channels. *Br J Pharmacol* 2009; 156: 1185–1195.
110. Jentsch TJ. Neuronal KCNQ potassium channels: physiology and role in disease. *Nat Rev Neurosci* 2000; 1: 21–30.
111. Mathie A and Veale EL. Two-pore domain potassium channels: potential therapeutic targets for the treatment of pain. *Pflugers Arch* 2015; 467: 931–943.
112. Carrasquillo Y and Nerbome JM. IA channels: diverse regulatory mechanisms. *Neuroscientist* 2014; 20: 104–111.
113. Phuket TR and Covarrubias M. Kv4 Channels underlie the subthreshold-operating A-type K-current in nociceptive dorsal root ganglion neurons. *Front Mol Neurosci* 2009; 2: 3.
114. Bahia PK, Suzuki R, Benton DC, et al. A functional role for small-conductance calcium-activated potassium channels in sensory pathways including nociceptive processes. *J Neurosci* 2005; 25: 3489–3498.
115. Wittekindt O, Jauch A, Burgert E, et al. The human small conductance calcium-regulated potassium channel gene (hSKCa3) contains two CAG repeats in exon 1, is on chromosome 1q21.3, and shows a possible association with schizophrenia. *Neurogenetics* 1998; 1: 259–265.
116. Zamponi GW, Lewis RJ, Todorovic SM, et al. Role of voltage-gated calcium channels in ascending pain pathways. Brain Res Rev 2009; 60: 84–89.

117. Catterall WA. Voltage-gated calcium channels. Cold Spring Harb Perspect Biol 2011; 3: 1–23.

118. Catterall WA, Perez-Reyes E, Snutch TP, et al. International union of pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 2005; 57: 411–425.

119. Furukawa T. Types of voltage-gated calcium channels: molecular and electrophysiological views. Curr Hypertens Res 2013; 9: 170–181.

120. Siau C and Bennett GJ. Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy. Anesth Analg 2006; 102: 1485–1490.

121. Jaggi AS and Singh N. Mechanisms in cancer-chemotherapy-induced peripheral neuropathy. Toxicology 2012; 291: 1–9.

122. Tomaszewski A and Busselberg D. Cisplatin modulates voltage gated channel currents of dorsal root ganglion neurons of rats. Neurotoxicology 2007; 28: 49–58.

123. Li Y, Adamek P, Zhang H, et al. Evaluation of cisplatin neurotoxicity in cultured rat dorsal root ganglia via cytosolic calcium accumulation. Balkan Med J 2016; 33: 144–151.

124. Aoki Y, Takahashi Y, Ohtori S, et al. Distribution and immunocytochemical characterization of dorsal root ganglion neurons innervating the lumbar intervertebral disc in rats: a review. Life Sci 2004; 74: 2627–2642.

125. Li Y, Adamek P, Zhang H, et al. The cancer chemotherapeutic paclitaxel increases human and rodent sensory neuron responses to TRPV1 by activation of TLR4. J Neurosci 2015; 35: 13487–13500.

126. Geisler S, Schopf CL and Obermair GJ. Emerging evidence for specific neuronal functions of auxiliary calcium channel alpha2delta subunits. Gen Physiol Biophys 2015; 34: 105–118.

127. Dolphin AC. Calcium channel auxiliary alpha2delta and beta subunits: trafficking and one step beyond. Nat Rev Neurosci 2012; 13: 542–555.

128. Dolphin AC. The alpha2delta subunits of voltage-gated calcium channels. Biochim Biophys Acta 2013; 1828: 1541–1549.

129. Tatsushima Y, Egashira N, Narishige Y, et al. Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: a retrospective study of 69 male patients receiving modified FOLFOX6 therapy. Biomed Pharmacother 2013; 67: 39–42.

130. Furukawa T, Nukada T, Miura R, et al. Differential blocking action of dihydropyridine Ca2+- antagonists on a T-type Ca2+- channel (alpha1G) expressed in Xenopus oocytes. J Cardiovasc Pharmacol 2005; 45: 241–246.

131. Furukawa T, Nukada T, Suzuki K, et al. Voltage and pH dependent block of cloned N-type Ca2+ channels by amiodipine. Br J Pharmacol 1997; 121: 1136–1140.

132. Furukawa T, Yamakawa T, Midera T, et al. Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther 1999; 291: 464–473.

133. Hayashi K, Wakino S, Sugano N, et al. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100: 342–353.

134. Yao K, Nagashima K and Miki H. Pharmacological, pharmacokinetic, and clinical properties of benidine hydrochloride, a novel, long-acting calcium channel blocker. J Pharmocol Sci 2006; 100: 243–261.

135. Zamponi GW, Striessnig J, Koschak A, et al. The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol Rev 2015; 67: 821–870.

136. Premkumar LS and Abooj M. TRP channels and analgesia. Life Sci 2013; 92: 415–424.

137. Brederson JD, Kym PR and Szallasi A. Targeting TRP channels for pain relief. Eur J Pharmacol 2013; 716: 61–76.

138. Wu LJ, Sweet TB and Clapham DE. International union of basic and clinical pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family. Pharmacol Rev 2010; 62: 381–404.

139. Mickle AD, Shepherd AJ and Mohapatra DP. Noiceptor TRP channels: sensory detectors and transducers in multiple pain pathologies. Pharmaceuticals (Basel) 2016; 9: E72.

140. Mandadi S and Roufogalis BD. ThermoTRP channels in nociceptors: taking a lead from capsaicin receptor TRPV1. Curr Neuropharmacol 2008; 6: 21–38.

141. Kono T, Satomi M, Suto M, et al. Oxaliplatin-induced neurotoxicity involves TRPM8 in the mechanism of acute hypersensitivity to cold sensation. Brain Behav 2012; 2: 68–73.

142. Cavaletti G and Marmirollo P. The role of growth factors in the prevention and treatment of chemotherapy-induced peripheral neurotoxicity. Curr Drug Saf 2006; 1: 35–42.

143. Price TJ, Das V and Dussor G. Adenosine monophosphate-activated protein kinase (AMPK) activators for the prevention, treatment and potential reversal of pathological pain. Curr Drug Targets 2016; 17: 908–920.

144. Chahine M and O’Leary ME. Regulation/modulation of sensory neuron sodium channels. Handb Exp Pharmacol 2014; 221: 111–135.

145. He C, Chen F, Li B, et al. Neurophysiology of HCN channels: from cellular functions to multiple regulations. Prog Neurobiol 2014; 112: 1–23.

146. Leo M, Argalski S, Schafer S, et al. Modulation of voltage-gated sodium channels by activation of tumor necrosis factor receptor-1 and receptor-2 in small DRG neurons of rats. Mediators Inflamm 2015; 2015: 124942.

147. Wu Z, Wang S, Gruber S, et al. Full-length membrane-bound tumor necrosis factor-alpha acts through tumor necrosis factor receptor 2 to modify phenotype of sensory neurons. Pain 2013; 154: 1778–1782.

148. Dina OA, Chen X, Reichling D, et al. Role of protein kinase Cepson and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. Neuroscience 2001; 108: 507–515.

149. Wang XM, Lebky TJ, Brel JM, et al. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine 2012; 59: 3–9.
150. Kiuchi N, Maeda T, Kobayashi Y, et al. Up-regulation of tumor necrosis factor-alpha in spinal cord contributes to vincristine-induced mechanical allodynia in mice. *Neurosci Lett* 2008; 445: 140–143.

151. Czeschik JC, Hagenacker T, Schafers M, et al. TNF-alpha differentially modulates ion channels of nociceptive neurons. *Neurosci Lett* 2008; 434: 293–298.

152. Ledeboer A, Jekich BM, Sloane EM, et al. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. *Brain Behav Immun* 2007; 21: 686–698.

153. Pevida M, Lastra A, Hidalgo A, et al. Spinal CCL2 and microglial activation are involved in paclitaxel-evoked cold hyperalgesia. *Brain Res Bull* 2013; 95: 21–27.

154. Popiolek-Barczyk K and Mika J. Targeting the microglial signaling pathways: new insights in the modulation of neuropathic pain. *Curr Med Chem* 2016; 23: 2908–2928.

155. Zhao R, Pei GX, Cong R, et al. PKC-NF-kappaB is involved in CCL2-induced Nav1.8 expression and channel function in dorsal root ganglion neurons. *Biosci Rep* 2014; 34: e00111.

156. Makker PG, Duffy SS, Lees JG, et al. Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. *PLoS One* 2017; 12: e0170814.

157. Zhang H, Boyette-Davis JA, Kosturakis AK, et al. Induction of monocyte chemoattractant protein-1 (MCP-1) and its receptor CCR2 in primary sensory neurons contributes to paclitaxel-induced peripheral neuropathy. *J Pain* 2013; 14: 1031–1044.

158. Zhou YQ, Liu Z, Liu ZH, et al. Interleukin-6: an emerging regulator of pathological pain. *J Neuroinflammation* 2016; 13: 141.

159. Kiuchi N, Maeda T, Kobayashi Y, et al. The critical role of invading peripheral macrophage-derived interleukin-6 in vincristine-induced mechanical allodynia in mice. *Eur J Pharmacol* 2008; 592: 87–92.

160. Langeslag M, Malsch P, Wellin A, et al. Reduced excitability of gp130-deficient nociceptors is associated with increased voltage-gated potassium currents and K<sub>Ca</sub>4 channel upregulation. *Pflugers Arch* 2014; 466: 2153–2165.

161. Starkweather A. Increased interleukin-6 activity associated with painful chemotherapy-induced peripheral neuropathy in women after breast cancer treatment. *Nurs Res Pract* 2010; 2010: 281531.

162. Wardill HR, Van Sebille YZ, Mander KA, et al. Toll-like receptor 4 signaling: a common biological mechanism of regimen-related toxicities: an emerging hypothesis for neuropathy and gastrointestinal toxicity. *Cancer Treat Rev* 2015; 41: 122–128.

163. Di Cesare Mannelli L, Zanardelli M, Failli P, et al. Oxaliplatin-induced oxidative stress in nervous system-derived cellular models: could it correlate with in vivo neuropathy? *Free Radic Biol Med* 2013; 61: 143–150.

164. del Camino D, Murphy S, Heiry M, et al. TRPAP1 contributes to cold hypersensitivity. *J Neurosci* 2010; 30: 15165–15174.

165. Joseph EK, Chen X, Bogen O, et al. Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. *J Pain* 2008; 9: 463–472.

166. Ossovskaia VS and Bunnett NW. Protease-activated receptors: contribution to physiology and disease. *Physiol Rev* 2004; 84: 579–621.

167. Amadesi S, Cottrell GS, Divino L, et al. Protease-activated receptor 2 sensitizes TRPV1 by protein kinase Cepsilon- and A-dependent mechanisms in rats and mice. *J Physiol* 2006; 575: 555–571.

168. Dai Y, Wang S, Tominaga M, et al. Sensitization of TRPAP1 by PAR2 contributes to the sensation of inflammatory pain. *J Clin Invest* 2007; 117: 1979–1987.

169. Grant A, Amadesi S and Bunnett NW. Frontiers in neuroscience-protease-activated receptors: mechanisms by which proteases sensitize trpv channels to induce neurogenic inflammation and pain. In: Liedtke WB and Heller (eds) TRP ion channel function in sensory transduction and cellular signaling cascades. Boca Raton (FL): CRC Press/Taylor & Francis -Taylor & Francis Group, LLC, 2007.

170. Argyriou AA, Polychronopoulos P, Iconomou G, et al. A review on oxaliplatin-induced peripheral nerve damage. *Cancer Treat Rev* 2008; 34: 368–377.

171. Avan A, Postma TJ, Ceresa C, et al. Platinum-induced neurotoxicity and preventive strategies: past, present, and future. *Oncologist* 2015; 20: 411–432.

172. Kaley TJ and Deangelis LM. Therapy of chemotherapy-induced peripheral neuropathy. *Br J Haematol* 2009; 145: 3–14.

173. Saif MW and Reardon J. Management of oxaliplatin-induced peripheral neuropathy. *Ther Clin Risk Manag* 2005; 1: 249–258.

174. Sheets PL, Heers C, Stoehr T, et al. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropionamide], lidocaine, and carbamazepine. *J Pharmacol Exp Ther* 2008; 326: 89–99.

175. Ibrahim SA, Albany Z and Albany C. Significant response to lacosamide in a patient with severe chemotherapy-induced peripheral neuropathy. *J Community Support Oncol* 2015; 13: 202–204.

176. Atreya S. Pregabalin in chemotherapy induced neuropathic pain. *Indian J Palliat Care* 2016; 22: 101–103.

177. Saif MW, Syrigos K, Kaley K, et al. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. *Anticancer Res* 2010; 30: 2927–2933.

178. Verma V, Singh N and Singh Jaggi A. Pregabalin in neuropathic pain: evidences and possible mechanisms. *Curr Neuropharmacol* 2014; 12: 44–56.

179. Albers JW, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. *Cochrane Database Syst Rev* 2014; CD005228.

180. Mielke S, Sparreboom A and Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. *Eur J Cancer* 2006; 42: 24–30.

181. Pasetto LM, D’Andrea MR, Rossi E, et al. Oxaliplatin-related neurotoxicity: how and why? *Crit Rev Oncol Hematol* 2006; 59: 159–168.
182. Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. *Clin Cancer Res* 2004; 10: 4055–4061.

183. Hochster HS, Grothey A and Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. *J Clin Oncol* 2007; 25: 4028–4029.

184. Grothey A, Hart LL, Rowland KM, et al. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONCePT trial. *J Clin Oncol* 2008; 26: 4010.

185. Grothey A, Nikcevich DA, Sloan JA, et al. Intravenous calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity (N08CB/Alliance). *J Clin Oncol* 2014; 32: 1941–1967.

186. Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2014; 32: 997–1005.

187. von Delius S, Eckel F, Wagenpfeil S, et al. Calcium and magnesium for oxaliplatin-induced sensory neuropathy in adjuvant colon cancer: NCCTG N04C7. *J Clin Oncol* 2011; 29: 421–427.

188. Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CR/Alliance). *J Clin Oncol* 2014; 32: 1051–1052.

189. von Delius S, Eckel F, Wagenpfeil S, et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study. *Invest New Drugs* 2007; 25: 173–180.

190. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. *J Clin Oncol* 1996; 14: 2101–2112.

191. Penz M, Kornek GV, Raderer M, et al. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. *Ann Oncol* 2001; 12: 421–422.

192. Leong SS, Tan EH, Fong KW, et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. *J Clin Oncol* 2003; 21: 1767–1774.

193. Openshaw H, Beamon K, Synold TW, et al. Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. *Clin Cancer Res* 2004; 10: 461–467.

194. Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. *J Clin Oncol* 2002; 20: 3478–3483.

195. Cascinu S, Cordella L, Del Ferro E, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. *J Clin Oncol* 1995; 13: 26–32.

196. Milla P, Airoldi M, Weber G, et al. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. *Anticancer Drugs* 2009; 20: 396–402.

197. Smyth JF, Bowman A, Perren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. *Ann Oncol* 1997; 8: 569–573.

198. Leal AD, Qin R, Atherton PJ, et al. North central cancer treatment group/alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. *Cancer* 2014; 120: 1890–1897.

199. Bianchi G, Vitali G, Caraceni A, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. *Eur J Cancer* 2005; 41: 1746–1750.

200. Hershman DL, Unger JM, Crew KD, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. *J Clin Oncol* 2013; 31: 2627–2633.

201. Pereira TV, Horwitz RI and Ioannidis JP. Empirical evaluation of very large treatment effects of medical interventions. *JAMA* 2012; 308: 1676–1684.

202. Sessler DI and Imrey PB. Clinical research methodology 1: study designs and methodologic sources of error. *Anesth Analg* 2015; 121: 1034–1042.

203. Sessler DI and Imrey PB. Clinical research methodology 2: observational clinical research. *Anesth Analg* 2015; 121: 1043–1051.

204. Sessler DI and Imrey PB. Clinical research methodology 3: randomized controlled trials. *Anesth Analg* 2015; 121: 1052–1064.

205. Esfahani A, Somi MH, Ayromlou H, et al. The effect of n-3 polyunsaturated fatty acids on incidence and severity of oxaliplatin induced peripheral neuropathy: a randomized controlled trial. *Biomark Res* 2016; 4: 13.

206. Ghoreishi Z, Esfahani A, Djjazayeri A, et al. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. *BMC Cancer* 2012; 12: 355.

207. Paice JA, Portenoy R, Lacchetti C, et al. Management of chronic pain in survivors of adult cancers: American society of clinical oncology clinical practice guideline. *J Clin Oncol* 2016; 34: 3325–3345.

208. Marmiroli P and Cavaletti G. Drugs for the treatment of peripheral neuropathies. *Expert Opin Pharmacother* 2016; 17: 381–394.

209. Cavaletti G and Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. *Curr Opin Neurol* 2015; 28: 500–507.
210. Janes K, Doyle T, Bryant L, et al. Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase. *Pain* 2013; 154: 2432–2440.

211. Todd AJ. Neuronal circuitry for pain processing in the dorsal horn. *Nat Rev Neurosci* 2010; 11: 823–836.

212. Waxman SG and Zamponi GW. Regulating excitability of peripheral afferents: emerging ion channel targets. *Nat Neurosci* 2014; 17: 153–163.

213. West SJ, Bannister K, Dickenson AH, et al. Circuitry and plasticity of the dorsal horn—toward a better understanding of neuropathic pain. *Neuroscience* 2015; 300: 254–275.

214. Hama A and Takamatsu H. Chemotherapy-induced peripheral neuropathic pain and rodent models. *CNS Neurol Disord Drug Targets* 2016; 15: 7–19.

215. Agarwal N, Offermanns S and Kuner R. Conditional gene deletion in primary nociceptive neurons of trigeminal ganglia and dorsal root ganglia. *Genesis* 2004; 38: 122–129.

216. Emery EC, Young GT, Berrocoso EM, et al. HCN2 ion channels play a central role in inflammatory and neuropathic pain. *Science* 2011; 333: 1462–1466.

217. Fricker FR, Zhu N, Tsantoulas C, et al. Sensory axon-derived neuregulin-1 is required for axoglial signaling and normal sensory function but not for long-term axon maintenance. *J Neurosci* 2009; 29: 7667–7678.

218. Minett MS, Nassar MA, Clark AK, et al. Distinct Nav1.7-dependent pain sensations require different sets of sensory and sympathetic neurons. *Nat Commun* 2012; 3: 791.

219. Nassar MA, Baker MD, Levato A, et al. Nerve injury induces robust alldynia and ectopic discharges in Nav1.3 null mutant mice. *Mol Pain* 2006; 2: 33.

220. Stirling LC, Forlani G, Baker MD, et al. Nociceptor-specific gene deletion using heterozygous NaV1.8-Cre recombinase mice. *Pain* 2005; 113: 27–36.

221. Weibel R, Reiss D, Karchewski L, et al. Mu opioid receptors on primary afferent nav1.8 neurons contribute to opiate-induced analgesia: insight from conditional knockout mice. *PLoS One* 2013; 8: e74706.

222. Zappia KJ, O’Hara CL, Moehring F, et al. Sensory neuron-specific deletion of trpA1 results in mechanical cutaneous sensory deficits. *eNeuro* 2017; 4: 1–14.

223. Zhao J, Yuan G, Cendan CM, et al. Nociceptor-expressed ephrin-B2 regulates inflammatory and neuropathic pain. *Mol Pain* 2010; 6: 77.

224. Bonin RP, Zurek AA, Yu J, et al. Hyperpolarization-activated current (Ih) is reduced in hippocampal neurons from Gabra5-/- mice. *PLoS One* 2013; 8: e58679.

225. Chen X, Shu S, Schwartz LC, et al. Homeostatic regulation of synaptic excitability: tonic GABAA receptor currents replace Ih in cortical pyramidal neurons of HCN1 knock-out mice. *J Neurosci* 2010; 30: 2611–2622.

226. Davis J, Maillet M, Miano JM, et al. Lost in transgenesis: a user’s guide for genetically manipulating the mouse in cardiac research. *Circ Res* 2012; 111: 761–777.

227. Jarvis MF, Scott VE, McGarraughty S, et al. A peripherally acting, selective T-type calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats. *Biochem Pharmacol* 2014; 89: 536–544.

228. Ziegler D, Duan WR, An G, et al. A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain. *Pain* 2015; 156: 2013–2020.

229. Shidahara Y, Ogawa S, Nakamura M, et al. Pharmacological comparison of a nonhuman primate and a rat model of oxaliplatin-induced neuropathic cold hypersensitivity. *Pharmacol Res Perspect* 2016; 4: e00216.

230. Bailey J and Taylor K. Non-human primates in neuroscience research: the case against its scientific necessity. *Altern Lab Anim* 2016; 44: 43–69.

231. Chambers SM, Qi Y, Mica Y, et al. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. *Nat Biotechnol* 2012; 30: 715–720.

232. Wheeler HE, Wing C, Delaney SM, et al. Modeling chemotherapeutic neurotoxicity with human induced pluripotent stem cell-derived neuronal cells. *PLoS One* 2015; 10: e0118020.

233. Sandoe J and Eggan K. Opportunities and challenges of pluripotent stem cell neurodegenerative disease models. *Nat Neurosci* 2013; 16: 780–789.

234. Muller M, Seufferlein T, Illing A, et al. Modelling human channelopathies using induced pluripotent stem cells: a comprehensive review. *Stem Cells Int* 2013; 2013: 496501.

235. Wainger BJ, Buttermore ED, Oliveira JT, et al. Modeling pain in vitro using nociceptor neurons reprogrammed from fibroblasts. *Nat Neurosci* 2015; 18: 17–24.

236. Mueggler T, Baltes C and Rudin M. Molecular neuroimaging in rodents: assessing receptor expression and function. *Eur J Neurosci* 2009; 30: 1860–1869.

237. Thompson SJ and Bushnell MC. Rodent functional and anatomical imaging of pain. *Neurosci Lett* 2012; 520: 131–139.

238. Tracey I. Neuroimaging mechanisms in pain: from discovery to translation. *Pain* 2017; 158: S115–S122.

239. Yu H, Senarathna J, Tyler BM, et al. Miniaturized optical neuroimaging in unrestrained animals. *Neuroimage* 2015; 113: 397–406.